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A B S T R A C T
Background
Xpert MTB/RIF and Xpert MTB/RIF Ultra (Xpert Ultra) are World Health Organization (WHO)-recommended rapid tests that simultaneously
detect tuberculosis and rifampicin resistance in people with signs and symptoms of tuberculosis. This review builds on our recent extensive
Cochrane Review of Xpert MTB/RIF accuracy.
Objectives
To compare the diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF for the detection of pulmonary tuberculosis and detection of
rifampicin resistance in adults with presumptive pulmonary tuberculosis. For pulmonary tuberculosis and rifampicin resistance, we also
investigated potential sources of heterogeneity.
We also summarized the frequency of Xpert Ultra trace-positive results, and estimated the accuracy of Xpert Ultra aJer repeat testing in
those with trace-positive results.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register, MEDLINE, Embase, Science Citation Index, Web of Science,
LILACS, Scopus, the WHO ICTRP, the ISRCTN registry, and ProQuest to 28 January 2020 with no language restriction.
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Selection criteria
We included diagnostic accuracy studies using respiratory specimens in adults with presumptive pulmonary tuberculosis that directly
compared the index tests. For pulmonary tuberculosis detection, the reference standards were culture and a composite reference standard.
For rifampicin resistance, the reference standards were culture-based drug susceptibility testing and line probe assays.
Data collection and analysis
Two review authors independently extracted data using a standardized form, including data by smear and HIV status. We assessed
risk of bias using QUADAS-2 and QUADAS-C. We performed meta-analyses comparing pooled sensitivities and specificities, separately
for pulmonary tuberculosis detection and rifampicin resistance detection, and separately by reference standard. Most analyses used
a bivariate random-eLects model. For tuberculosis detection, we estimated accuracy in studies in participants who were not selected
based on prior microscopy testing or history of tuberculosis. We performed subgroup analyses by smear status, HIV status, and history of
tuberculosis. We summarized Xpert Ultra trace results.
Main results
We identified nine studies (3500 participants): seven had unselected participants (2834 participants). All compared Xpert Ultra and
Xpert MTB/RIF for pulmonary tuberculosis detection; seven studies used a paired comparative accuracy design, and two studies used a
randomized design. Five studies compared Xpert Ultra and Xpert MTB/RIF for rifampicin resistance detection; four studies used a paired
design, and one study used a randomized design. Of the nine included studies, seven (78%) were mainly or exclusively in high tuberculosis
burden countries. For pulmonary tuberculosis detection, most studies had low risk of bias in all domains.
Pulmonary tuberculosis detection
Xpert Ultra pooled sensitivity and specificity (95% credible interval) against culture were 90.9% (86.2 to 94.7) and 95.6% (93.0 to 97.4)
(7 studies, 2834 participants; high-certainty evidence) versus Xpert MTB/RIF pooled sensitivity and specificity of 84.7% (78.6 to 89.9) and
98.4% (97.0 to 99.3) (7 studies, 2835 participants; high-certainty evidence). The diLerence in the accuracy of Xpert Ultra minus Xpert MTB/
RIF was estimated at 6.3% (0.1 to 12.8) for sensitivity and −2.7% (−5.7 to −0.5) for specificity. If the point estimates for Xpert Ultra and
Xpert MTB/RIF are applied to a hypothetical cohort of 1000 patients, where 10% of those presenting with symptoms have pulmonary
tuberculosis, Xpert Ultra will miss 9 cases, and Xpert MTB/RIF will miss 15 cases. The number of people wrongly diagnosed with pulmonary
tuberculosis would be 40 with Xpert Ultra and 14 with Xpert MTB/RIF.
In smear-negative, culture-positive participants, pooled sensitivity was 77.5% (67.6 to 85.6) for Xpert Ultra versus 60.6% (48.4 to 71.7) for
Xpert MTB/RIF; pooled specificity was 95.8% (92.9 to 97.7) for Xpert Ultra versus 98.8% (97.7 to 99.5) for Xpert MTB/RIF (6 studies).
In people living with HIV, pooled sensitivity was 87.6% (75.4 to 94.1) for Xpert Ultra versus 74.9% (58.7 to 86.2) for Xpert MTB/RIF; pooled
specificity was 92.8% (82.3 to 97.0) for Xpert Ultra versus 99.7% (98.6 to 100.0) for Xpert MTB/RIF (3 studies).
In participants with a history of tuberculosis, pooled sensitivity was 84.2% (72.5 to 91.7) for Xpert Ultra versus 81.8% (68.7 to 90.0) for Xpert
MTB/RIF; pooled specificity was 88.2% (70.5 to 96.6) for Xpert Ultra versus 97.4% (91.7 to 99.5) for Xpert MTB/RIF (4 studies).
The proportion of Ultra trace-positive results ranged from 3.0% to 30.4%. Data were insuLicient to estimate the accuracy of Xpert Ultra
repeat testing in individuals with initial trace-positive results.
Rifampicin resistance detection
Pooled sensitivity and specificity were 94.9% (88.9 to 97.9) and 99.1% (97.7 to 99.8) (5 studies, 921 participants; high-certainty evidence)
for Xpert Ultra versus 95.3% (90.0 to 98.1) and 98.8% (97.2 to 99.6) (5 studies, 930 participants; high-certainty evidence) for Xpert MTB/RIF.
The diLerence in the accuracy of Xpert Ultra minus Xpert MTB/RIF was estimated at −0.3% (−6.9 to 5.7) for sensitivity and 0.3% (−1.2 to 2.0)
for specificity. If the point estimates for Xpert Ultra and Xpert MTB/RIF are applied to a hypothetical cohort of 1000 patients, where 10% of
those presenting with symptoms have rifampicin resistance, Xpert Ultra will miss 5 cases, and Xpert MTB/RIF will miss 5 cases. The number
of people wrongly diagnosed with rifampicin resistance would be 8 with Xpert Ultra and 11 with Xpert MTB/RIF.
We identified a higher number of rifampicin resistance indeterminate results with Xpert Ultra, pooled proportion 7.6% (2.4 to 21.0)
compared to Xpert MTB/RIF pooled proportion 0.8% (0.2 to 2.4). The estimated diLerence in the pooled proportion of indeterminate
rifampicin resistance results for Xpert Ultra versus Xpert MTB/RIF was 6.7% (1.4 to 20.1).
Authors' conclusions
Xpert Ultra has higher sensitivity and lower specificity than Xpert MTB/RIF for pulmonary tuberculosis, especially in smear-negative
participants and people living with HIV. Xpert Ultra specificity was lower than that of Xpert MTB/RIF in participants with a history of
tuberculosis. The sensitivity and specificity trade-oL would be expected to vary by setting. For detection of rifampicin resistance, Xpert
Ultra and Xpert MTB/RIF had similar sensitivity and specificity. Ultra trace-positive results were common.
Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary
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Xpert Ultra and Xpert MTB/RIF provide accurate results and can allow rapid initiation of treatment for rifampicin-resistant and multidrug-
resistant tuberculosis.
P L A I N   L A N G U A G E   S U M M A R Y
Xpert Ultra compared to Xpert MTB/RIF for diagnosing pulmonary tuberculosis and rifampicin resistance in adults
Why is improving the diagnosis of pulmonary tuberculosis important?
Tuberculosis is one of the leading causes of death worldwide. While tuberculosis is largely curable when detected early and eLectively
treated, around 1.2 million people died of tuberculosis in 2019. Xpert MTB/RIF and Xpert Ultra (the newest version) are World Health
Organization-recommended rapid tests that simultaneously detect tuberculosis and rifampicin resistance in people with tuberculosis
symptoms. Rifampicin is an important antituberculosis drug. Not recognizing tuberculosis when it is present (false negative) may result
in severe illness and death, and an increased risk of infecting others. An incorrect diagnosis of tuberculosis (false positive) may result in
anxiety, additional testing, unnecessary treatment, and medication side eLects.
What is the aim of this review?
To determine how accurate Xpert Ultra is compared with Xpert MTB/RIF for diagnosing pulmonary tuberculosis and rifampicin resistance
in adults. An extensive review of Xpert MTB/RIF accuracy was recently published as a Cochrane Review.
What was studied in this review?
We compared the diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF with results primarily measured against culture (detection of
pulmonary tuberculosis) and drug susceptibility testing and line probe assays (detection of rifampicin resistance).
What are the main results in this review?
Nine studies (3500 participants) compared Xpert Ultra to Xpert MTB/RIF for diagnosing pulmonary tuberculosis, and five studies (930
participants) compared Xpert Ultra to Xpert MTB/RIF for rifampicin resistance.
How confident are we in the results of this review?
Confident. The review included suLicient studies and participants and used optimum reference standards. In the comparison between
Xpert Ultra and Xpert MTB/RIF, most studies were at low risk of bias.
Who do the results of this review apply to?
People considered to have pulmonary tuberculosis.
What are the implications of this review?
The results of these studies indicate that, in theory, for a population of 1000 people where 100 of those presenting with symptoms have
pulmonary tuberculosis, Xpert Ultra will miss 9 cases, and Xpert MTB/RIF will miss 15 cases. The number of people wrongly diagnosed with
pulmonary tuberculosis would be 40 with Xpert Ultra, and 14 with Xpert MTB/RIF.
The results of these studies indicate that, in theory, for a population of 1000 people where 100 of those have rifampicin resistance, Xpert
Ultra will miss 5 cases, and Xpert MTB/RIF will miss 5 cases. The number of people wrongly diagnosed with rifampicin resistance would
be 8 with Xpert Ultra, and 11 with Xpert MTB/RIF.
How up-to-date is this review?
28 January 2020.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Xpert Ultra versus Xpert MTB/RIF for the detection of pulmonary tuberculosis*
Review question: what is the diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF for the detection of pulmonary tuberculosis?
Patients/population: adults with presumptive pulmonary tuberculosis. Participants were unselected, meaning they were not enrolled in a study based on microscopy
smear results or history of tuberculosis
Role: an initial test
Index tests: Xpert Ultra and Xpert MTB/RIF
Threshold for index tests: an automated result is provided
Reference standards: solid or liquid culture
Studies: cross-sectional and cohort studies
Setting: primary care facilities and local hospitals
Xpert Ultra sensitivity 90.9% (86.2 to 94.7) and specificity 95.6% (93.0 to 97.4)
Xpert MTB/RIF sensitivity 84.7% (78.6 to 89.9) and specificity 98.4% (97.0 to 99.3)
Number of results per 1000 patients tested (95% CrI)**
Prevalence 2.5% Prevalence 10% Prevalence 30%
Test result




































2 fewer FN in Xpert Ultra 6 fewer FN in Xpert Ultra 19 fewer FN in Xpert Ultra
983 (7) ⊕⊕⊕⊕
High
932 (907 to 950) 959 (946 to 968) 860 (837 to 877) 886 (873 to 894) 669 (651 to 682) 689 (679 to 695)True nega-
tives (TN)











































































































































































































43 (25 to 68) 16 (7 to 29) 40 (23 to 63) 14 (6 to 27) 31 (18 to 49) 11 (5 to 21)False posi-
tives (FP)
27 more FP in Xpert Ultra 26 more FP in Xpert Ultra 20 more FP in Xpert Ultra
Abbreviations: CrI: credible interval
GRADE certainty of the evidence
High: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially
different.
Low: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
*The results presented in this table should not be interpreted in isolation from the results of individual included studies contributing to each summary test accuracy measure.
**95% credible limits were estimated based on those around the point estimates for pooled sensitivity and specificity. Prevalence estimates were suggested by the World Health
Organization Global Tuberculosis Programme. The median tuberculosis prevalence in the included studies was 30.1% (range 12.8% to 72.2%).
***In the Xpert Ultra analysis there were 1851 participants. Piersimoni 2019 reported three non-determinate results for Xpert Ultra and two for Xpert MTB/RIF, accounting for the
small diLerence in the total number of participants.
 
 
Summary of findings 2.   Xpert Ultra versus Xpert MTB/RIF for the detection of rifampicin resistance*
Review question: what is the diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF for the detection of rifampicin resistance?
Patients/population: adults with presumptive pulmonary tuberculosis
Role: an initial test
Index tests: Xpert Ultra and Xpert MTB/RIF
Threshold for index tests: an automated result is provided
Reference standards: drug susceptibility testing, line probe assay
Studies: cross-sectional and cohort studies
Setting: primary care facilities and local hospitals
Xpert Ultra sensitivity 94.9% (88.9 to 97.9) and specificity 99.1% (97.7 to 99.8)
Xpert MTB/RIF sensitivity 95.3% (90.0 to 98.1) and specificity 98.8% (97.2 to 99.6)
Number of results per 1000 patients tested (95% CrI)**Test result




























































































































































































































0 fewer TP in Xpert Ultra 0 fewer TP in Xpert Ultra 1 fewer TP in Xpert Ultra
1 (0 to 2) 1 (0 to 2) 5 (2 to 11) 5 (2 to 10) 8 (3 to 18) 7 (3 to 15)False nega-
tives (FN)
0 fewer FN in Xpert Ultra 0 fewer FN in Xpert Ultra 1 more FN in Xpert Ultra
238 (5) ⊕⊕⊕⊕
High
971 (957 to 977) 968 (953 to 976) 892 (879 to 897) 889 (875 to 896) 842 (830 to 847) 840 (826 to 847)True nega-
tives (TN)
3 more TN in Xpert Ultra 3 more TN in Xpert Ultra 2 more TN in Xpert Ultra
9 (3 to 23) 12 (4 to 27) 8 (3 to 21) 11 (4 to 25) 8 (3 to 20) 10 (3 to 24)False posi-
tive (FP)
3 fewer FP in Xpert Ultra 3 fewer FP in Xpert Ultra 2 fewer FP in Xpert Ultra
692 (5) ⊕⊕⊕⊕
High
Abbreviations: CrI: credible interval
GRADE certainty of the evidence
High: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially
different.
Low: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
*The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure.
**Prevalence estimates were suggested by the World Health Organization Global Tuberculosis Programme. The median prevalence of rifampicin resistance in the included studies
was 23.6% (range 1.9% to 31.8%). Credible limits were estimated based on those around the point estimates for pooled sensitivity and specificity.
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B A C K G R O U N D
Tuberculosis is a leading cause of infectious disease-related death
and is one of the top 10 causes of death worldwide (WHO Global
tuberculosis report 2020). In 2019, 10 million people developed
tuberculosis disease, a number that over the past several years
has been decreasing slowly (WHO Global tuberculosis report 2020).
Of the 10 million tuberculosis cases, approximately 8% occurred
among people living with HIV. When tuberculosis is detected early
and eLectively treated, the disease is largely curable. However,
in 2019, around 1.2 million HIV-negative people and 208,000 HIV-
positive people died from tuberculosis (WHO Global tuberculosis
report 2020). The World Health Organization (WHO) estimates
that, from 2000 to 2019, more than 60 million lives were saved
by diagnosing and treating tuberculosis. The COVID-19 pandemic
threatens to reverse the gains made in recent years. A modelling
study by the WHO suggests that there could have been between
200,000 and 400,000 additional tuberculosis deaths in 2020 if, over
a period of three months, 25% to 50% fewer people were detected
with and treated for tuberculosis (WHO Global tuberculosis report
2020).
Drug-resistant tuberculosis is a serious threat to global health.
For the purpose of surveillance and treatment, drug-resistant
tuberculosis is classified as rifampicin-resistant tuberculosis,
multidrug-resistant tuberculosis (MDR-TB), and extensively drug-
resistant tuberculosis (XDR-TB). MDR-TB is defined as resistance
to at least isoniazid and rifampicin, the two most important first-
line antituberculosis drugs. XDR-TB is defined as MDR-TB plus
resistance to at least one drug in the fluoroquinolone class and
one of the second-line injectable agents. In 2019, there were
approximately half a million new cases of rifampicin-resistant
tuberculosis (of which 78% had MDR-TB) worldwide, with India
(27%), China (14%), and the Russian Federation (9%) accounting
for the largest burden, and 12,350 cases of XDR-TB (WHO Global
tuberculosis report 2020). Globally in 2019, 59% of bacteriologically
confirmed new cases were tested for rifampicin resistance, an
increase from 51% in 2018 (WHO Global tuberculosis report 2020).
In 2014, the World Health Assembly unanimously approved the
WHO End TB Strategy, a 20-year strategy devised to end the
global tuberculosis epidemic (WHO 2015a). Early diagnosis of
tuberculosis, including universal drug susceptibility testing and
systematic screening of contacts and high-risk groups, is a key part
of the strategy.
The same or similar text appears in the Background and Methods
sections in related protocols and reviews (Kay 2020; Kohli 2021;
Shapiro 2020; Vonasek 2020).
Target condition being diagnosed
Pulmonary tuberculosis
Tuberculosis is caused by the bacterium Mycobacterium
tuberculosis (M tuberculosis) and is spread from person to person
through the air (CDC 2020). Tuberculosis most commonly aLects
the lungs (pulmonary tuberculosis), but may aLect any organ or
tissue outside of the lungs (extrapulmonary tuberculosis). Signs
and symptoms of pulmonary tuberculosis include cough, fever,
chills, night sweats, weight loss, haemoptysis (coughing up blood),
and fatigue. Signs and symptoms of extrapulmonary tuberculosis
depend on the site of disease.
Tuberculosis treatment regimens must contain multiple drugs to
which the organisms are sensitive to cure tuberculosis and avoid
selection for drug resistance.
Rifampicin resistance
Rifampicin inhibits bacterial DNA-dependent ribonucleic acid
(RNA) polymerase, encoded by the RNA polymerase gene (rpoB)
(Hartmann 1967). Resistance to this drug has mainly been
associated with mutations in a limited region of the rpoB gene
(Telenti 1993). Rifampicin resistance may occur alone or in
association with resistance to isoniazid and other drugs. In high
MDR-TB settings, the presence of rifampicin resistance alone may
serve as a proxy for MDR-TB (WHO 2011a). People with drug-
resistant tuberculosis can transmit the infection to others. The
drugs used to treat MDR-TB are less potent and more toxic than
the drugs used to treat drug-susceptible tuberculosis, historically
requiring two years or more of therapy. The WHO has issued
recommendations that all individuals with MDR-TB or rifampicin-
resistant tuberculosis, including those who are also resistant to
fluoroquinolones, may benefit from eLective all-oral treatment
regimens (WHO Consolidated Guidelines (Module 4) 2020).
Index test(s)
Xpert MTB/RIF and Xpert MTB/RIF Ultra (Xpert Ultra, the newest
version of Xpert MTB/RIF) (Cepheid Inc, Sunnyvale, USA) are the
index tests. The index tests are nucleic acid amplification tests
(NAAT; i.e. molecular tests) used for diagnosing tuberculosis and
rifampicin-resistant tuberculosis. Xpert MTB/RIF and Xpert Ultra
cartridges are used with the GeneXpert system (Cepheid 2018;
Cepheid 2019). Xpert MTB/RIF and Xpert Ultra are able to detect
both M tuberculosis complex and rifampicin resistance within two
hours aJer starting the test, with minimal hands-on technical
time. With Xpert MTB/RIF and Xpert Ultra, unlike in conventional
NAAT, sample processing and polymerase chain reaction (PCR)
amplification and detection are integrated into a single, self-
enclosed test unit, the GeneXpert cartridge. Following sample
loading, all steps in the assay are completely automated and self-
contained. In addition, the assays' sample reagent, used to liquefy
sputum, has potent tuberculocidal (the ability to kill tuberculosis
bacteria) properties and so largely eliminates biosafety concerns
during the test procedure (Banada 2010). Except as described below
for Ultra trace call results, a single Xpert MTB/RIF or Xpert Ultra
run will provide both detection of tuberculosis and detection of
rifampicin resistance. One cannot deselect testing for rifampicin
resistance and only run the assay for tuberculosis detection.
The development of Xpert MTB/RIF was a major step toward
improving detection of tuberculosis and rifampicin resistance
globally (Boehme 2010; Small 2011). Since Xpert MTB/RIF was
released, there have been four generations (G1, G2, G3, and G4) of
the test involving diLerent soJware and cartridge combinations.
Although in comparison with smear microscopy, Xpert MTB/RIF
has increased sensitivity for pulmonary tuberculosis (Steingart
2014), the test has suboptimal sensitivity in people with smear-
negative and HIV-associated tuberculosis. A Cochrane Review
on the diagnostic accuracy of Xpert MTB/RIF for pulmonary
tuberculosis found pooled sensitivity and specificity (95% credible
interval (CrI)) of 85% (82 to 88) and 98% (97 to 98) (70 studies,
37,237 unselected participants; high-certainty evidence) (Horne
2019). However, Xpert MTB/RIF sensitivity was decreased in people
with smear-negative culture-positive disease, pooled sensitivity of
Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary
tuberculosis (Review)
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67% (62 to 72), and people living with HIV, pooled sensitivity of 81%
(75 to 86) (Horne 2019). Xpert MTB/RIF versions have also had some
limitations in detecting rifampicin resistance.
In order to overcome these limitations, Cepheid developed Xpert
Ultra, a re-engineered assay using a newly developed cartridge that
is run on the same device aJer a soJware upgrade. To improve
sensitivity for tuberculosis detection, Xpert Ultra incorporates
two diLerent multi-copy amplification targets and a larger DNA
reaction chamber than Xpert MTB/RIF (WHO 2017). A laboratory
study reported that the limit of detection (the lowest number of
colony-forming units (CFUs) per sample that can be reproducibly
distinguished from negative samples with 95% confidence) using
Xpert Ultra improved to 15.6 CFU/mL of sputum compared to 112.6
CFU/mL for Xpert MTB/RIF (Chakravorty 2017).
Importantly, Xpert Ultra added a new semiquantitative category
for tuberculosis detection that was not present in Xpert MTB/
RIF: "trace call" corresponds to the lowest bacillary load for M
tuberculosis detection (WHO 2017). This new category is reported as
MTB trace DETECTED. No rifampicin resistance results are available
(reported as INDETERMINATE) for people with trace results. As with
Xpert MTB/RIF, Xpert Ultra detects both live and dead bacteria.
To address limitations in rifampicin resistance detection, Xpert
Ultra uses melting temperature-based analysis, in lieu of real-
time PCR analysis with Xpert MTB/RIF. Melting temperature-
based analysis allows Xpert Ultra to better distinguish resistance-
conferring mutations from silent mutations (Global Laboratory
Initiative 2017).
The test procedure may be used directly on clinical specimens,
either raw sputum specimens or sputum pellets created aJer
decontaminating and concentrating the sputum (Blakemore 2010).
In both cases, the test material is combined with the assay sample
reagent (sodium hydroxide and isopropanol), mixed by hand or
vortex, and incubated at room temperature for 15 minutes. The
reagent:sample volume ratio is 2:1 for unprocessed sputum and
3:1 for sputum pellets. AJer the incubation step, 2 mL of the
treated specimen are transferred to the cartridge and the run is
initiated. The manufacturer does not specifically mention the use
of the index tests with frozen specimens (Cepheid 2018; Cepheid
2019). As with Xpert MTB/RIF, Xpert Ultra using the GeneXpert
system requires an uninterrupted and stable electrical power
supply, temperature control, and yearly calibration of the cartridge
modules (Global Laboratory Initiative 2019). Like previous Xpert
cartridge generations, Xpert Ultra can be performed by operators
with minimal technical expertise (Theron 2014b). The time to run
the assay is shorter for Xpert Ultra (65 to 87 minutes) than for Xpert
MTB/RIF (112 minutes) (Global Laboratory Initiative 2017).
Clinical pathway
Xpert Ultra and Xpert MTB/RIF are used for the diagnosis of
tuberculosis and rifampicin resistance. Figure 1 shows the clinical
pathway and presents the context in which the index tests might be
used. The target condition is pulmonary tuberculosis. Individuals
to be evaluated for pulmonary tuberculosis are adults with signs
or symptoms suggestive of tuberculosis, such as cough, fever, night
sweats, weight loss, haemoptysis, and fatigue, or with an abnormal
chest x-ray suggestive of tuberculosis. Additionally, people who are
known to have tuberculosis and are at risk for rifampicin-resistant
tuberculosis or MDR-TB (e.g. those with a previous history of
tuberculosis treatment or those who have an inadequate response
to antituberculosis treatment) may undergo Xpert Ultra testing to
evaluate for rifampicin resistance.
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Figure 1.   The clinical pathway describes how people might present and the point in the pathway at which they
would be considered for testing with Xpert MTB/RIF or Xpert Ultra. Abbreviations: DST: drug susceptibility testing;
INH: isoniazid; MDR-TB: multidrug-resistant tuberculosis; MTB: Mycobacterium tuberculosis; mWRD: molecular
WHO-recommended rapid diagnostic; PLHIV: people living with HIV; RIF: rifampicin; TB: tuberculosis; Ultra: Xpert
Ultra; WHO: World Health Organization. 1Persons to be evaluated for TB include adults and children with signs or
symptoms suggestive of TB, or with a chest X-ray with abnormalities suggestive of TB. This algorithm may also be
followed for the diagnosis of extrapulmonary TB using CSF, lymph node and other tissue specimens.
2Programs may consider collecting two specimens upfront. The first specimen should be promptly tested using the
molecular WRD test. The second specimen may be used for the additional testing described in this algorithm. For
persons being evaluated for pulmonary TB, sputum is the preferred specimen. Tissue biopsy samples are diLicult or
impossible to obtain repeatedly; therefore, they should be tested with as many methods as possible (e.g. molecular
WRD, culture, DST or histology).
3Molecular WRD tests appropriate for this algorithm include Xpert MTB/RIF, Xpert Ultra, Truenat MTB, Truenat MTB
Plus and TB-LAMP.
4“MTB detected (not trace)” includes MTB detected as high, moderate, low or very low. These categories apply
to the original Xpert MTB/RIF and Xpert Ultra tests. Results of the Truenat MTB and MTB Plus tests and the TB-
LAMP test also fall into the category of “MTB detected (not trace)”. Additional footnotes are explained in WHO
Consolidated Guidelines (Module 4) 2020. This algorithm for the use of a molecular WHO-recommended rapid
diagnostic (WRD), which includes Xpert Ultra and Xpert MTB/RIF, comes from the WHO operational handbook on
tuberculosis (WHO Consolidated Guidelines (Module 4) 2020). Copyright © [2020] [World Health Organization]:
reproduced with permission.
 
The downstream consequences of testing include the following.
• True-positive (TP): patients would benefit from rapid diagnosis
and appropriate treatment.
• True-negative (TN): patients would be spared unnecessary
treatment and would benefit from reassurance and pursuit of an
alternative diagnosis.
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• False-positive (FP): patients would probably experience anxiety
and morbidity caused by additional testing, unnecessary
treatment, and possible adverse events; possible stigma
associated with a tuberculosis or MDR-TB diagnosis; and the
chance that a false-positive result may halt further diagnostic
evaluation.
• False-negative (FN): increased risk of morbidity and mortality
and delayed treatment initiation; risk of ongoing tuberculosis
transmission.
Settings of interest
We were interested in how the index tests performed in people
with presumptive pulmonary tuberculosis, who were evaluated as
they would be in routine practice, most oJen in local hospitals or
primary care centres. The index tests may have the greatest impact
on health when used in a setting such as a primary healthcare
facility, where treatment can be started the same day as testing or
as soon as possible.
Role of index test(s)
We were interested in the following roles for testing.
I. Xpert Ultra and Xpert MTB/RIF for the detection of pulmonary
tuberculosis
Index test used as an initial test replacing smear microscopy
and culture for the diagnosis of pulmonary tuberculosis in adults
with presumptive pulmonary tuberculosis (WHO Consolidated
Guidelines (Module 3) 2020). An initial test does not mean that other
tests will follow.
II. Xpert Ultra and Xpert MTB/RIF for the detection of rifampicin
resistance
Index test used as an initial test replacing culture and phenotypic
drug susceptibility testing for the diagnosis of rifampicin-resistant
tuberculosis in adults with presumptive pulmonary tuberculosis
(WHO Consolidated Guidelines (Module 3) 2020).
As mentioned, in high MDR-TB settings the presence of rifampicin
resistance alone may serve as a proxy for MDR-TB. Xpert Ultra
and Xpert MTB/RIF do not eliminate the need for subsequent
culture and phenotypic drug susceptibility testing (DST), which are
required to monitor treatment progress and to detect resistance to
drugs other than rifampicin, respectively.
Alternative test(s)
In this section, we describe selected alternative tests for the
detection of pulmonary tuberculosis and rifampicin resistance. For
a comprehensive review of alternative tests, we refer the reader
to several excellent resources (Branigan 2019; Lewinsohn 2017;
Unitaid 2017).
Smear microscopy is the examination of smears for acid-
fast bacilli (tuberculosis bacteria) under a microscope. The
examination may be performed by light microscopy (Ziehl-
Neelsen), fluorescence microscopy, or light-emitting diode (LED)
fluorescence microscopy. Advantages of smear microscopy include
its simplicity, low cost, speed, and high specificity in high
tuberculosis burden areas. In addition, smear microscopy identifies
the most infectious people with tuberculosis. Smear microscopy
can be performed in basic laboratories. Drawbacks of smear
microscopy include the need for specialized training and its
relatively low sensitivity, 50% to 60% on average for a direct
smear (Steingart 2006b). Around 5000 to 10,000 organisms per
millilitre must be present in the specimen for tuberculosis
bacteria to be visible by microscopy (American Thoracic Society
2000). Although the sensitivity of microscopy can be improved
by approximately 10% with fluorescence (Steingart 2006a), a
large number of tuberculosis cases will still go undiagnosed.
Smear-negative tuberculosis is disproportionately higher in HIV-
positive than in HIV-negative individuals, accounting for 24% to
61% of all pulmonary cases in people living with HIV (Getahun
2007; Perkins 2007). Microscopy cannot distinguish between
drug-susceptible tuberculosis and drug-resistant tuberculosis. The
WHO recommends that microscopy as the initial diagnostic
test be replaced with WHO-recommended rapid tests that
can simultaneously detect tuberculosis and tuberculosis drug
resistance (WHO Consolidated Guidelines (Module 3) 2020).
Mycobacterial culture is a method used to grow bacteria on
nutrient-rich media. In comparison with microscopy, a positive
culture requires only around 100 organisms per millilitre, and
therefore can detect lower numbers of tuberculosis bacteria
(American Thoracic Society 2000). Additionally, culture is essential
for species identification and DST. However, culture is a relatively
complex and slow procedure. Solid culture typically takes between
four to eight weeks for results, and liquid culture, although more
sensitive and rapid than solid culture, requires up to six weeks and
is more prone to contamination (WHO 2015b). In addition, culture
requires specialized laboratories and highly skilled staL. Culture is
the reference standard for pulmonary tuberculosis in this review.
NAAT are molecular systems that can detect small quantities of
genetic material (DNA or RNA) from microorganisms, such as M
tuberculosis. The key advantage of NAAT is that they are rapid
diagnostic tests, potentially providing results in a few hours. A
variety of molecular amplification methods are available, of which
PCR is the most common. NAAT are available as commercial kits
and in-house tests (based on a protocol developed in a laboratory)
and are routinely used in high-income countries for tuberculosis
detection. In-house PCR is widely used in low-income countries
because these tests are less expensive than commercial kits.
However, in-house PCR is known to produce inconsistent results
(Flores 2005). In addition to Xpert MTB/RIF and Xpert Ultra, the
WHO recommends Truenat tuberculosis technology (Truenat MTB,
MTB Plus and MTB-RIF Dx assays) (Molbio Diagnostics, Goa, India)
to detect tuberculosis and rifampicin-resistant tuberculosis (WHO
Consolidated Guidelines (Module 3) 2020).
Alternative molecular methods for DST include the commercial
line probe assays GenoType MTBDRplus assay (MTBDRplus,
Hain LifeScience, Nehren, Germany) and the Nipro NTM+MDRTB
detection kit 2 (Nipro, Tokyo, Japan), which detect the presence
of mutations associated with drug resistance to isoniazid and
rifampicin (Nathavitharana 2017). MTBDRplus is the most widely
studied line probe assay. Advantages of line probe assays are
that they can provide a result for the detection of tuberculosis
and drug resistance in one to two days. Drawbacks are that line
probe assays are expensive and need to be used in intermediate
and central laboratories (Unitaid 2017). The WHO recommends
that for individuals with a sputum smear-positive specimen or
a cultured tuberculosis isolate, commercial molecular line probe
assays may be used as the initial test instead of phenotypic culture-
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based DST to detect resistance to rifampicin and isoniazid (WHO
Consolidated Guidelines (Module 3) 2020). Other molecular assays
for the detection of tuberculosis and resistance to rifampicin and
isoniazid are in development (Walzl 2018).
Alere Determine TB LAM Ag (AlereLAM) (Alere Inc, Waltham, USA) is
a commercially available point-of-care test for tuberculosis disease
(pulmonary and extrapulmonary tuberculosis). The test detects
lipoarabinomannan (LAM), a component of the bacterial cell wall,
which is present in the urine of some people with tuberculosis.
AlereLAM is performed by placing urine on one end of a test
strip, with results appearing as a band on the strip if tuberculosis
is present. The test is simple, requires no special equipment,
and shows results in 25 minutes. This urine test has potential
advantages over sputum-based testing due to the ease of sample
collection. The accuracy of urinary LAM detection is improved
among people living with HIV with advanced immunosuppression
(Bjerrum 2019). The use of AlereLAM in HIV-positive adult inpatients
was shown to reduce mortality in two randomized trials (Gupta-
Wright 2018; Peter 2016). Based on evidence from the randomized
trials and a Cochrane Review (Bjerrum 2019), the WHO currently
recommends that AlereLAM be used to assist in the diagnosis
of active tuberculosis in HIV-positive adults, adolescents, and
children (WHO Consolidated Guidelines (Module 3) 2020). The key
change from the WHO 2015 guidelines is broadening the indication
for the use of lateral flow LAM among HIV-positive inpatients
with signs and symptoms of active tuberculosis (pulmonary and
extrapulmonary); the test is now recommended for all such
patients, irrespective of their CD4 count (WHO Consolidated
Guidelines (Module 3) 2020).
Fujifilm SILVAMP TB LAM (FujiLAM, co-developed by Foundation
for Innovative New Diagnostics (FIND), Geneva, Switzerland and
Fujifilm, Tokyo, Japan) is a new, urine-based, point-of-care test for
tuberculosis diagnosis in people living with HIV. In an individual
participant data meta-analysis that included five cohorts of people
living with HIV, FujiLAM was found to have superior sensitivity,
70.7% (95% confidence interval 59.0 to 80.8), compared to AlereLAM
sensitivity of 42.3% (31.7 to 51.8), against a microbiological
reference standard; FujiLAM had lower specificity, 90.9% (87.2 to
93.7), compared to AlereLAM specificity of 95.3% (92.2 to 97.7)
(Broger 2020).
Rationale
Xpert Ultra and Xpert MTB/RIF are rapid tests that may provide
benefits for patients (earlier diagnosis and the opportunity
to begin earlier, appropriate treatment) and for public health
(opportunities to interrupt tuberculosis transmission), especially in
high tuberculosis burden countries.
Since 2010, the WHO has recommended the use of Xpert
MTB/RIF as the preferred initial diagnostic test for people
thought to have MDR-TB or HIV-associated tuberculosis (strong
recommendation, moderate-certainty evidence) (WHO 2011b). In
2013, the WHO expanded the recommendations, stating that Xpert
MTB/RIF may be used rather than conventional microscopy and
culture as the initial diagnostic test in all adults suspected of
having tuberculosis (conditional recommendation acknowledging
resource implications, high-[certainty] evidence) (WHO 2013). In
addition, the WHO recommended that following an Xpert MTB/
RIF test that demonstrates rifampicin resistance, subsequent drug
susceptibility testing (e.g. using a line probe assay to second-line
drugs) remains essential to detect resistance to drugs other than
rifampicin (WHO 2013). In 2017, based on a non-inferiority analysis
of Xpert Ultra compared with Xpert MTB/RIF, the WHO stated that
recommendations on the use of Xpert MTB/RIF also apply to the use
of Xpert Ultra as the initial diagnostic test for all adults and children
with signs and symptoms of tuberculosis (WHO 2017).
In December 2019, the WHO convened a Guideline Development
Group to update the recommendations on the use of molecular
assays intended as initial tests for the diagnosis of pulmonary
and extrapulmonary tuberculosis and rifampicin resistance. To
extend the work of our previous Cochrane Review (Horne 2019),
we performed this review update to inform updates to WHO policy
(WHO Consolidated Guidelines (Module 3) 2020).
O B J E C T I V E S
Primary objectives
To compare the diagnostic accuracy of Xpert Ultra and Xpert MTB/
RIF for the detection of pulmonary tuberculosis and detection
of rifampicin resistance in adults with presumptive pulmonary
tuberculosis.
Secondary objectives
For detection of pulmonary tuberculosis, to investigate the eLects
of potential sources of heterogeneity such as smear status, HIV
status, and history of tuberculosis on test accuracy.
For detection of rifampicin resistance, to investigate the eLect of
smear status (smear positive and smear negative) on test accuracy.
To summarize the frequency of Xpert Ultra trace-positive results.
To estimate the accuracy of Xpert Ultra aJer repeat testing in those
with trace-positive results.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included cross-sectional and cohort type diagnostic accuracy
studies that directly compared the index tests in participants
with presumptive pulmonary tuberculosis. These study designs
included paired and randomized comparative accuracy studies.
Paired comparative accuracy studies are those in which each
participant receives both index tests. Randomized comparative
accuracy studies are those which randomly allocate participants
to index tests, with each participant receiving only one index
test. 'Presumptive pulmonary tuberculosis' refers to a patient
who presents with symptoms or signs suggestive of tuberculosis.
We included studies where the index tests were evaluated for
both pulmonary tuberculosis and rifampicin resistance, pulmonary
tuberculosis alone, or rifampicin resistance alone. We also included
randomized controlled trials that evaluated the use of the index(s)
test on patient health outcomes, but that also reported sensitivity
and specificity. Although the study design was a randomized trial
for the purpose of determining the impact of the test on participant
outcomes, the study design was a cross-sectional study for the
purpose of determining the diagnostic accuracy of the index tests
in this review. However, we did not identify any randomized
controlled trials. We used abstracts to identify published studies
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and included these publications if they met our inclusion criteria.
We only included studies that reported data comparing the index
test(s) to an acceptable reference standard from which we could
extract true-positive (TP), true-negative (TN), false-positive (FP),
and false-negative (FN) values. The index tests could be assessed
alone or together with other tests.
We included studies that evaluated the index tests in HIV-positive
people irrespective of tuberculosis symptoms, for example HIV-
positive people being assessed for antiretroviral therapy. We
included these studies for the following reasons: the risk of
developing tuberculosis is much higher in people living with
HIV, estimated to be 20 to 37 times higher in HIV-positive
individuals than in HIV-negative individuals (Getahun 2010); signs
and symptoms of tuberculosis in people living with HIV vary,
which makes it challenging to determine when to consider a
diagnosis of tuberculosis; and many HIV-positive people in low-
income countries develop tuberculosis as the first manifestation of
AIDS.
We excluded case reports and studies with a case-control design,
the latter because these types of studies are prone to bias,
particularly studies enrolling participants with severe disease and
healthy participants without disease. We excluded studies of the
index tests in people with diabetes but without tuberculosis
symptoms, and studies designed to find people with active
tuberculosis in community settings. We excluded drug resistance
surveys.
Participants
We included studies that enrolled adults, aged 15 years or older,
with presumptive pulmonary tuberculosis, rifampicin-resistant
tuberculosis, or MDR-TB. For tuberculosis detection, we were
interested in people who were not currently on tuberculosis
treatment or those on treatment for less than seven days.
Tuberculosis treatment might interfere with the confirmation of
tuberculosis on culture (the reference standard for this review). If
the treatment status of the participants was unclear, we contacted
primary study authors for this information.
We included studies that assessed the diagnostic accuracy of
Xpert Ultra and Xpert MTB/RIF using sputum and other respiratory
specimens, such as fluid obtained from bronchial alveolar lavage
and tracheal aspiration, consistent with the intended use of the
manufacturer (Cepheid 2018), and studies from all types of health
facilities and all laboratory levels (peripheral, intermediate, and
central) from all countries. We excluded studies where the age of
the participants was unknown.
Index tests
The index tests were Xpert Ultra and Xpert MTB/RIF.
Index test results are automatically generated (i.e. there is a single
threshold), and the user is provided with a printable test result as
follows.
Xpert Ultra
• MTB (M tuberculosis) DETECTED HIGH; RIF (rifampicin)
Resistance DETECTED
• MTB DETECTED MEDIUM; RIF Resistance DETECTED
• MTB DETECTED LOW; RIF Resistance DETECTED
• MTB DETECTED VERY LOW; RIF Resistance DETECTED
• MTB DETECTED HIGH; RIF Resistance NOT DETECTED
• MTB DETECTED MEDIUM; RIF Resistance NOT DETECTED
• MTB DETECTED LOW; RIF Resistance NOT DETECTED
• MTB DETECTED VERY LOW; RIF Resistance NOT DETECTED
• MTB DETECTED HIGH; RIF Resistance INDETERMINATE
• MTB DETECTED MEDIUM; RIF Resistance INDETERMINATE
• MTB DETECTED LOW; RIF Resistance INDETERMINATE
• MTB DETECTED VERY LOW; RIF Resistance INDETERMINATE
• MTB Trace DETECTED; RIF Resistance INDETERMINATE
• INVALID (the presence or absence of MTB cannot be determined)
• ERROR (the presence or absence of MTB cannot be determined)
• NO RESULT (the presence or absence of MTB cannot be
determined)
We considered a trace result to mean MTB (M tuberculosis)
DETECTED.
Xpert MTB/RIF
• MTB (M tuberculosis) DETECTED; RIF (rifampicin) Resistance
DETECTED
• MTB DETECTED; RIF Resistance NOT DETECTED
• MTB detected; RIF Resistance INDETERMINATE
• MTB NOT DETECTED
• INVALID (the presence or absence of MTB cannot be determined)
• ERROR (the presence or absence of MTB cannot be determined)
• NO RESULT (the presence or absence of MTB cannot be
determined
Target conditions
The target conditions were active pulmonary tuberculosis and
rifampicin resistance.
Reference standards
For pulmonary tuberculosis, the reference standards were solid
culture or automated liquid culture.
• Pulmonary tuberculosis present was defined as a positive M
tuberculosis culture.
• Pulmonary tuberculosis absent was defined as a negative M
tuberculosis culture.
We also included a composite reference standard. The diagnosis of
pulmonary tuberculosis was defined as a positive culture or clinical
criteria specified by the primary study authors. Clinical criteria
might include cough longer than two weeks, fever, night sweats, or
weight loss and radiographic findings consistent with pulmonary
tuberculosis.
• Pulmonary tuberculosis present was defined as a positive M
tuberculosis culture or meeting composite reference standard
criteria.
• Pulmonary tuberculosis absent was defined as a negative
M tuberculosis culture and not meeting composite reference
standard criteria.
For rifampicin resistance, the reference standards were culture-
based drug susceptibility testing (DST), and line probe assays
Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary
tuberculosis (Review)










Cochrane Database of Systematic Reviews
(LPA) (WHO Consolidated Guidelines (Module 3) 2020). Acceptable
methods for DST are the proportion method, performed on solid
media, such as Lowenstein-Jensen, and use of a commercial liquid
culture system, such as Mycobacteria Growth Indicator Tube (MGIT)
960 automated mycobacterial detection system (BD, USA).
• Rifampicin resistance present was defined as a positive culture-
based DST (or LPA) result for resistance.
• Rifampicin resistance absent was defined as a negative culture-
based DST (or LPA) result for resistance (i.e. rifampicin
susceptible).
Search methods for identification of studies
We attempted to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, and
ongoing).
Electronic searches
We searched the following databases on 11 October 2018, 23 August
2019, and 28 January 2020, using the search terms and strategy
described in Appendix 1:
Cochrane Infectious Diseases Group Specialized Register; MEDLINE
(Ovid, from 1966); Embase (Ovid, from 1974); Science Citation
Index - Expanded (from 1900), Conference Proceedings Citation
Index - Science (CPCI-S, from 1990), and BIOSIS Previews (from
1926); all three from the Web of Science; Scopus (Elsevier,
from 1970); Latin American Caribbean Health Sciences Literature
database (LILACS) (BIREME, from 1982). We also searched
the US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (clinicaltrials.gov), the WHO International Clinical
Trials Registry Platform (ICTRP; www.who.int/trialsearch), and
the ISRCTN registry (www.isrctn.com/) for trials in progress, and
ProQuest Dissertations & Theses A&I (from 1990) for dissertations.
In order to identify other systematic reviews and meta-analyses,
we performed additional searches on 28 May 2020 in MEDLINE
(PubMed), Embase (Ovid), and the Cochrane Library, applying
filters for systematic reviews (https://www.sign.ac.uk/what-we-
do/methodology/search-filters/) to search terms for Xpert and
tuberculosis.
Searching other resources
We reviewed the reference lists of included articles and any
relevant review articles identified through the above methods. We
also contacted researchers at the Foundation for Innovative New
Diagnostics (FIND), the WHO Global Tuberculosis Programme, and
other experts in the field of tuberculosis diagnostics for information
on ongoing and unpublished studies.
Data collection and analysis
Selection of studies
We used Covidence to manage the selection of studies
(Covidence). Two review authors independently scrutinized titles
and abstracts identified from literature searching to identify
potentially eligible studies. We retrieved the article of any citation
identified by any review author for full-text review. Two review
authors independently assessed the full-text articles for inclusion
using predefined inclusion and exclusion criteria, resolving any
discrepancies by discussion with a third review author. We recorded
all studies excluded aJer full-text assessment and their reasons
for exclusion in the Characteristics of excluded studies table. We
illustrated the study selection process in a PRISMA diagram (Moher
2009). We included search results from the original review and re-
evaluated previously included studies to determine if the studies
met the refined inclusion criteria.
Data extraction and management
We extracted data on the following characteristics (Appendix 2).
• Author, publication year, study design, country where the
study was located, level of laboratory services, clinical setting
(outpatient, inpatient, or both outpatient and inpatient), and
whether the test was run at point of care
• Population characteristics: age, gender, smear status, HIV status
• Index test(s), Xpert Ultra and Xpert MTB/RIF
• Reference standard
• Condition of the specimen (fresh or frozen)
• Quality Assessment of Studies of Diagnostic Accuracy - Revised
(QUADAS-2) items, Whiting 2011, and QUADAS-C, Yang B 2020
• Number of TP, FP, FN, TN (i.e. true positives, false positives, false
negatives, true negatives) and trace results
• Number of non-determinate results for the detection of
pulmonary tuberculosis
• Number of indeterminate results for the detection of rifampicin
resistance
We classified country income status as either low- and middle-
income or high-income, according to the World Bank List of
Economies (World Bank 2020). In addition, we classified ‘country'
as being high burden or not high burden for tuberculosis, TB/HIV,
or MDR-TB, according to the WHO post-2015 era classification (WHO
Global tuberculosis report 2020). A country could be classified as
high burden for one, two, or all three of the high-burden categories.
Although the manufacturer recommends use of fresh specimens,
several studies used frozen specimens, so we also extracted
this information. We investigated the influence of condition of
specimen in a sensitivity analysis.
Regarding the definition of smear positivity, as most of the included
studies performed the index tests in intermediate-level or central-
level laboratories, we assumed that these studies adhered to the
revised definition of a new sputum smear-positive pulmonary
tuberculosis case based on the presence of at least one acid-fast
bacillus in at least one sputum sample in countries with a well-
functioning external quality assurance system (WHO 2007).
We followed Cochrane policy, which states that "authors of primary
studies will not extract data from their own study or studies.
Instead, another author will extract these data, and check the
interpretation against the study report and any available study
registration details or protocol".
Assessment of methodological quality
We used the Quality Assessment of Diagnostic Accuracy Studies
(QUADAS-2) tool to assess the quality of the included studies
(Whiting 2011). QUADAS-2 consists of four domains: patient
selection, index test, reference standard, and flow and timing. We
assessed all domains for risk of bias and the first three domains
for concerns regarding applicability. Two review authors, working
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independently, completed QUADAS-2, resolving any disagreements
through discussion. We have presented the results of this quality
assessment in text, tables, and graphs. In addition, we used
QUADAS-C (C stands for comparison) to assess risk of bias in
the included studies. QUADAS-C was designed to be an extension
to QUADAS-2, with a set of additional questions. QUADAS-C
results in separate 'Risk of bias' judgements for comparative
accuracy studies. QUADAS-C assesses risk of bias in the same four
domains as QUADAS-2: (1) patient selection, (2) index tests, (3)
reference standard, and (4) flow and timing, but does not assess
applicability concerns. The version of QUADAS-C used in this review
(v2019.10.10) is a preliminary version which may be revised further
(Yang B 2020). QUADAS-2 and QUADAS-C tools tailored to this
review are described in Appendix 3.
Statistical analysis and data synthesis
We performed descriptive analyses for the results of the included
studies using Stata 15 (Stata 2017). We determined sensitivity
and specificity estimates and 95% confidence intervals (CIs)
for individual studies and generated forest plots using Review
Manager 5 (Review Manager 2020). Whenever possible, we
included nontuberculous mycobacteria (NTM) as non-tuberculosis
for specificity determinations. We chose to use data that were
not subject to discrepant analyses (unresolved data) owing to the
potential for bias (Hadgu 2005).
We carried out meta-analyses to estimate the pooled sensitivity
and specificity of the index tests separately for tuberculosis
detection and rifampicin resistance detection. We performed
analyses separately by reference standard. Whenever possible,
we determined pooled estimates using an adaptation of the
bivariate random-eLects model of Reitsma 2005, which uses the
exact binomial likelihood for the observed proportions (Chu 2006).
The bivariate random-eLects approach allowed us to calculate
the pooled estimates of sensitivity and specificity while dealing
with potential sources of variation caused by (1) imprecision
of sensitivity and specificity estimates within individual studies;
(2) correlation between sensitivity and specificity across studies;
and (3) variation in sensitivity and specificity between studies.
For Xpert Ultra and Xpert MTB/RIF for detection of pulmonary
tuberculosis among smear-positive individuals (described below),
we performed a univariate analysis. For the primary analysis
of Xpert Ultra versus Xpert MTB/RIF for tuberculosis detection,
we estimated accuracy using studies that did not preselect
participants based on prior microscopy testing or that primarily
included participants with a history of tuberculosis. In addition,
we determined predictive values at a pretest probability of 10%, a
value suggested by the WHO.
Rifampicin resistance detection
For analysis of Xpert Ultra or Xpert MTB/RIF accuracy for detection
of rifampicin resistance, we included participants who
• were culture-positive;
• had a valid phenotypic DST or LPA result;
• were Xpert Ultra or Xpert MTB/RIF tuberculosis-positive; and
• had a valid Xpert Ultra or Xpert MTB/RIF result for rifampicin
resistance, detected or not detected (susceptible).
Sensitivity = Xpert Ultra (or Xpert MTB/RIF) rifampicin resistance
detected/phenotypic DST or LPA rifampicin-resistant.
Specificity = Xpert Ultra (or Xpert MTB/RIF) rifampicin resistance not
detected/phenotypic DST or LPA rifampicin-susceptible.
Comparison of Xpert Ultra and Xpert MTB/RIF
We performed meta-analyses of the accuracy of Xpert Ultra and
Xpert MTB/RIF in studies that made direct comparisons between
Xpert Ultra versus Xpert MTB/RIF (Takwoingi 2013). We extracted
the median and the 95% credible interval (CrI) for all parameters
of interest from samples of the posterior distributions. The 95%
CrI is the Bayesian equivalent of the classical (frequentist) 95%
confidence interval (CI). We compared the accuracy of Xpert Ultra
versus Xpert MTB/RIF by estimating the diLerence in their pooled
sensitivities and the diLerence in their pooled specificities and
calculated the probability that Xpert Ultra accuracy exceeds (or is
less than) that of Xpert MTB/RIF accuracy.
We estimated all models using a Bayesian approach with low-
information prior distributions using OpenBUGS soJware (Version
3.2.3) (Lunn 2009) and R (R Core Team 2019). Under the Bayesian
approach, all unknown parameters must be provided a prior
distribution that defines the range of possible values of the
parameter and the likelihood of each of those values based on
information external to the data. In order to let the observed data
determine the final results, we chose to use low-information prior
distributions over the pooled sensitivity and specificity parameters
and their between-study standard deviation parameters. We
summarize the model and the OpenBUGS program we used to
implement it in the Statistical Appendix (Appendix 4). As meta-
analysis models may be sensitive to the choice of prior distributions
over between-study standard deviation parameters, we performed
sensitivity analyses using alternative prior distributions that are
less informative, allowing a wider range of possible values. We
noted no appreciable change in pooled accuracy parameters
but, as expected, found that the posterior credible intervals and
prediction intervals were slightly wider. Information from the prior
distribution is combined with the likelihood of the observed data in
accordance with Bayes theorem to obtain a posterior distribution
for each unknown parameter (Appendix 5).
Using a sample from the posterior distribution, we can obtain
various descriptive statistics of interest. We estimated the median
pooled sensitivity and specificity and their 95% CrIs. The median
or the 50% quantile is the value below which lies 50% of the
posterior sample. We reported the median because the posterior
distributions of some parameters may be skewed, and the median
would be considered a better point estimate of the unknown
parameter than the mean in such cases. The 95% CrI is the Bayesian
equivalent of the classical (frequentist) 95% CI. (We have indicated
95% CI for individual study estimates and 95% CrI for pooled study
estimates, as appropriate). The 95% CrI may be interpreted as an
interval that has a 95% probability of capturing the true value of
the unknown parameter, given the observed data and the prior
information.
We generated plots using R (R Core Team 2019).
Approach to inconclusive index test results
The index tests report an inconclusive test result for unexpected
results. The proportion of inconclusive (non-determinate) results
for the detection of pulmonary tuberculosis is the number of tests
classified as INVALID, ERROR, or NO RESULT divided by the total
number of index tests performed. The proportion of inconclusive
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(indeterminate) results for the detection of rifampicin resistance is
the number of tests classified as MTB DETECTED; RIF (rifampicin)
resistance INDETERMINATE divided by the total number of index
test-positive results. We used a Bayesian hierarchical model for a
single proportion to estimate the pooled proportion of inconclusive
tests results. For participants with trace results on Xpert Ultra,
rifampicin resistance is always reported as INDETERMINATE. As we
found very few inconclusive results reported, we excluded these
results from the quantitative analysis and separately reported the
pooled proportion of non-determinate and indeterminate index
test results. In addition, we compared the pooled proportion
(expressed as a percentage) of indeterminate results for Xpert Ultra
versus Xpert MTB/RIF by estimating the diLerence in their pooled
proportions with the probability that these diLerences exceed zero.
Investigations of heterogeneity
We visually inspected forest plots and summary receiver operating
characteristics (SROC) plots to explore heterogeneity in the
sensitivity and specificity estimates for Xpert Ultra and Xpert MTB/
RIF. We performed the following subgroup analyses.
Detection of pulmonary tuberculosis
For the detection of pulmonary tuberculosis, we performed
comparative analyses for Xpert Ultra versus Xpert MTB/RIF with
respect to smear status (smear negative and smear positive), HIV
status (positive and negative), and history of tuberculosis (yes or
no). We performed these analyses by fitting a bivariate model
to each subgroup. We extracted the median and the 95% CrI for
the diLerence in the pooled sensitivities and the diLerence in the
pooled specificities, respectively, of Xpert Ultra versus Xpert MTB/
RIF. When there were at least four studies in a subgroup, we also
calculated the probability that the diLerence exceeds zero in each
case.
Among smear-positive individuals, we performed a univariate
analysis because in several studies the value for true negatives plus
false positives was zero, and specificity was inestimable.
Detection of rifampicin resistance
For the detection of rifampicin resistance, we compared Xpert Ultra
and Xpert MTB/RIF accuracy with respect to smear status (smear
positive and smear negative).
Xpert Ultra trace results
Summary of Xpert Ultra trace-positive results and repeated testing of
Ultra trace specimens
Xpert Ultra added a new result category, trace, that corresponds
to the lowest bacillary load for M tuberculosis detection (WHO
2017). This new category is reported as MTB trace DETECTED. We
summarized the frequency of Xpert Ultra trace-positive results, as
well as the frequency of trace results in individuals with a history
of tuberculosis. We also summarized the accuracy of Xpert Ultra
repeated test for diagnosing pulmonary tuberculosis in people who
have an initial Ultra trace result.
Nontuberculous mycobacteria
NTM, such as M avium complex and M abscessus, constitute
a multi-species group of environmental mycobacteria that
can cause pulmonary disease in humans that clinically
resembles tuberculosis. People living with HIV with severe
immunosuppression are particularly vulnerable to infections
caused by NTM (Gopinath 2010). Previous studies have shown
that Xpert MTB/RIF does not cross-react with other mycobacterial
species (Helb 2010). We summarized data for NTM separately by
determining the proportion (expressed as a percentage) of false-
positive Xpert Ultra and Xpert MTB/RIF results in specimens that
grew NTMs.
Sensitivity analyses
For Xpert Ultra for detection of pulmonary tuberculosis, we
performed sensitivity analyses by limiting inclusion in the meta-
analysis based on the following criteria.
• Studies that included only untreated participants. We excluded
studies that did not explicitly state that they included only
untreated participants.
• Studies that used liquid culture as the reference standard.
• Studies where a consecutive or random sample of participants
was enrolled.
• Studies where the reference standard was blinded.
• Studies that only used fresh specimens.
• Studies that accounted for all participants in the analysis. We
excluded studies where we answered no or unclear to the
QUADAS-2 flow and timing signalling question: Were all patients
included in the analysis?
We did not perform sensitivity analyses for Xpert MTB/RIF, as we
performed these analyses in the previous update of this review.
Most of these analyses included greater than 50 studies (Horne
2019).
Assessment of reporting bias
We chose not to carry out formal assessments of publication bias
using methods such as funnel plots or regression tests, because
such techniques have not been helpful for diagnostic test accuracy
studies (Macaskill 2010). As Xpert Ultra and Xpert MTB/RIF are
produced by only one manufacturer and subjected to considerable
scrutiny, we believe that reporting bias was minimal.
Summary of findings and assessment of the certainty of the
evidence
We assessed the certainty of evidence using the GRADE
approach for diagnostic studies (Balshem 2011; Schünemann 2008;
Schünemann 2016). As recommended, we rated the certainty of the
evidence as either high (not downgraded), moderate (downgraded
by one level), low (downgraded by two levels), or very low
(downgraded by more than two levels) based on five domains: risk
of bias, indirectness, inconsistency, imprecision, and publication
bias. For each outcome, the certainty of evidence started as high
when there were high-quality studies (cross-sectional or cohort
studies) that enrolled participants with diagnostic uncertainty. If
there was a reason for downgrading, we used our judgement to
classify the reason as either serious (downgraded by one level)
or very serious (downgraded by two levels). Two review authors
discussed the judgements of the certainty of the evidence and
applied GRADE in the following way (GRADEpro GDT; Schünemann
2020a; Schünemann 2020b).
• Risk of bias: we used QUADAS-2 to assess risk of bias.
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• Indirectness: we assessed indirectness in relation to the
population (including disease spectrum), setting, interventions,
and outcomes (accuracy measures). We also used prevalence as
a guide to whether there was indirectness in the population.
• Inconsistency: GRADE recommends downgrading for
unexplained inconsistency in sensitivity and specificity
estimates. We carried out prespecified analyses to investigate
potential sources of heterogeneity and did not downgrade when
we believed we could explain inconsistency in the accuracy
estimates.
• Imprecision: we considered a precise estimate to be one that
would allow a clinically meaningful decision. We considered the
width of the CrI and asked ourselves, would we make a diLerent
decision if the lower or upper boundary of the CrI represented
the truth? In addition, we worked out projected ranges for TP,
FN, TN, and FP for a given prevalence of tuberculosis and made
judgements on imprecision from these calculations.
• Publication bias: we rated publication bias as undetected (not
serious). We considered the comprehensiveness of the literature
search and outreach to researchers in tuberculosis; the presence
of only studies that produce precise estimates of high accuracy
despite small sample size; and knowledge about studies that
were conducted, but are not published.
R E S U L T S
Results of the search
We identified and screened a total of 1054 records for inclusion in
this review update. Of these, we assessed 74 full-text papers against
our inclusion criteria. We excluded 67 papers for the following
reasons: Xpert Ultra not evaluated (n = 52), extrapulmonary
tuberculosis (n = 5), paediatric population (n = 3), case-control
study (n = 2), inappropriate reference standard (n = 1), only culture-
positive specimens were tested and Xpert MTB/RIF not evaluated
(n = 1), did not include respiratory specimens (n = 1), community-
based screening (n = 1), and could not obtain full text (n = 1).
We identified eight eligible publications including nine unique
studies; one publication contributed two distinct cohorts (Mishra
2020a; Mishra 2020b). All included studies compared Xpert Ultra
and Xpert MTB/RIF for the detection of pulmonary tuberculosis
(Berhanu 2018; Chakravorty 2017; Dorman 2018; Mishra 2020a;
Mishra 2020b; Opota 2019; Pereira 2020; Piersimoni 2019; Wang
2019). Of the total nine studies, five studies compared Xpert
Ultra and Xpert MTB/RIF for the detection of rifampicin resistance
(Chakravorty 2017; Dorman 2018; Mishra 2020b; Piersimoni 2019;
Wang 2019). Figure 2 shows the flow of studies in the review. We
recorded the excluded studies, including selected studies from the
previous Cochrane Review (Horne 2019), and the reasons for their
exclusion in the Characteristics of excluded studies table.
 
Figure 2.   PRISMA flow diagram of studies in the review. *One publication contributed two distinct studies, which
were classified as Mishra 2020a and Mishra 2020b.
 
Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary
tuberculosis (Review)










Cochrane Database of Systematic Reviews
Methodological quality of included studies
Studies evaluating Xpert Ultra and Xpert MTB/RIF for the
detection of pulmonary tuberculosis
QUADAS-2
Figure 3 shows the risk of bias and applicability concerns for nine
studies evaluating Xpert Ultra and Xpert MTB/RIF for the detection
of pulmonary tuberculosis.
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Figure 3.   Risk of bias and applicability concerns summary for detection of pulmonary tuberculosis: review authors'
judgements about each domain for each included study.
 
In the patient selection domain, we considered six studies (67%) to
have low risk of bias because the study enrolled a consecutive or
random sample of eligible participants and avoided inappropriate
exclusions (Berhanu 2018; Dorman 2018; Mishra 2020a; Opota 2019;
Pereira 2020; Piersimoni 2019). We considered two studies (22%) to
have high risk of bias: one study exclusively enrolled participants
who had recently received tuberculosis treatment (Mishra 2020b),
and one study exclusively enrolled smear-negative participants
(Wang 2019). We considered one study to have unclear risk of
bias because the manner of patient selection was not reported
(Chakravorty 2017). With respect to applicability, we considered
four studies (44%) to have low concern because participants
in these studies were evaluated in primary care facilities, local
hospitals, or both settings (Berhanu 2018; Dorman 2018; Mishra
2020a; Pereira 2020). We considered three studies (33%) to have
high concern: two studies because participants were evaluated
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exclusively as inpatients in tertiary care centres (Piersimoni 2019;
Wang 2019), and one study because the setting was a hospital
performing a laboratory-based evaluation for the purpose of
airborne isolation (Opota 2019). We considered two studies (22%)
to have unclear concern because we could not tell (Chakravorty
2017; Mishra 2020b).
In the index test domain, we considered all studies to have low risk
of bias because the results of the index tests (Xpert Ultra and Xpert
MTB/RIF) are automatically generated. Regarding applicability, we
considered all studies to have low concern.
In the reference standard domain, we considered seven studies
(78%) to have low risk of bias because the results of the reference
standard were interpreted without knowledge of the results of the
index test (Berhanu 2018; Chakravorty 2017; Dorman 2018; Mishra
2020a; Mishra 2020b; Opota 2019; Piersimoni 2019). We considered
two studies (22%) to have unclear risk of bias because information
about blinding was not reported (Pereira 2020; Wang 2019).
Regarding applicability, we considered seven studies (78%) to have
low concern because these studies performed a test to identify M
tuberculosis species (speciation) (Berhanu 2018; Chakravorty 2017;
Dorman 2018; Mishra 2020a; Mishra 2020b; Piersimoni 2019; Wang
2019), and two studies (22%) to have unclear concern because we
could not tell (Opota 2019; Pereira 2020).
In the flow and timing domain, we considered all studies (100%) to
have low risk of bias because all participants were included in the
analysis.
QUADAS-C
Appendix 6 shows risk of bias for nine studies comparing Xpert Ultra
and Xpert MTB/RIF. Seven studies used a paired diagnostic accuracy
design (Chakravorty 2017; Dorman 2018; Mishra 2020a; Opota 2019;
Pereira 2020; Piersimoni 2019; Wang 2019), and two studies used a
randomized design (Berhanu 2018; Mishra 2020b).
In the patient selection domain, we considered six studies (78%) to
have low risk of bias: in five studies participants were consecutively
enrolled (Dorman 2018; Mishra 2020a; Opota 2019; Pereira 2020;
Piersimoni 2019), and in one study participants were randomly
enrolled (Berhanu 2018). In Berhanu 2018, all participants received
Xpert MTB/RIF, and the order by which participants were selected
to receive Xpert Ultra or a third index test (not included in this
review) was randomized. We considered three studies (33%) to
have high risk of bias: one study did not report the manner of
participant selection (Chakravorty 2017); one study exclusively
enrolled participants who had recently received tuberculosis
treatment (Mishra 2020b); and one study exclusively enrolled
smear-negative participants (Wang 2019).
In the index test domain, we judged low risk of bias for all studies.
In the reference standard domain, we considered seven studies
(78%) to have low risk of bias because the results of the reference
standard were interpreted without knowledge of the results of the
index test (Berhanu 2018; Chakravorty 2017; Dorman 2018; Mishra
2020a; Mishra 2020b; Opota 2019; Piersimoni 2019). We considered
two studies (22%) to have unclear risk of bias because information
about blinding was not reported (Pereira 2020; Wang 2019).
In the flow and timing domain, we judged low risk of bias for all
studies.
Studies evaluating Xpert Ultra and Xpert MTB/RIF for the
detection of rifampicin resistance
QUADAS-2
Figure 4 shows risk of bias and applicability concerns for the five
studies evaluating Xpert Ultra and Xpert MTB/RIF for rifampicin
resistance detection.
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Figure 4.   Risk of bias and applicability concerns summary for detection of rifampicin resistance: review authors'
judgements about each domain for each included study.
 
In the patient selection domain, we considered two studies
(40%) to have low risk of bias because the studies enrolled
a consecutive or random sample of eligible participants and
avoided inappropriate exclusions (Dorman 2018; Piersimoni 2019).
We considered two studies (40%) to have high risk of bias:
one study exclusively enrolled participants who had recently
received tuberculosis treatment (Mishra 2020b), and one study
preselected participants on the basis of their sputum specimens
being paucibacillary (smear-negative) (Wang 2019). We considered
one study (20%) to have unclear risk of bias because the manner
of participant selection was not reported (Chakravorty 2017).
Regarding applicability, we considered one study (20%) to have
low concern because participants in this study were evaluated
in primary care facilities and local hospitals (Dorman 2018). We
considered two studies (40%) to have high concern because
participants were evaluated exclusively as inpatients in tertiary
care centres (Piersimoni 2019; Wang 2019). We considered the
remaining two studies (40%) to have unclear concern because we
could not tell (Chakravorty 2017; Mishra 2020b).
In the index test domain, we considered all studies to have low
risk of bias because the results of the index tests (Xpert Ultra and
Xpert MTB/RIF) are automatically generated; the user is provided
with printable test results; and the test threshold is prespecified.
Regarding applicability, with respect to both Xpert Ultra and Xpert
MTB/RIF, we considered all studies to have low concern.
In the reference standard domain, we considered four studies (80%)
to have low risk of bias because the results of the reference standard
were interpreted without knowledge of the results of the index
test (Chakravorty 2017; Dorman 2018; Mishra 2020b; Piersimoni
2019). We considered one study (20%) to have unclear risk of bias
because information on blinding was not reported (Wang 2019).
With respect to applicability in the reference standard domain, we
considered all studies to have low concern because all specimens
had already been speciated and identified as M tuberculosis in these
studies.
In the flow and timing domain, we considered four studies (80%)
to have low risk of bias because all participants were included in
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the analysis. We considered one study to have unclear risk of bias
because, in comparison to Xpert MTB/RIF, Xpert Ultra had a higher
number of rifampicin resistance indeterminate results which were
not included in the accuracy estimates (Mishra 2020b).
QUADAS-C
Appendix 7 shows risk of bias for five studies comparing Xpert Ultra
and Xpert MTB/RIF. Four studies used a paired diagnostic accuracy
design (Chakravorty 2017; Dorman 2018; Piersimoni 2019; Wang
2019), and one study used a randomized design (Mishra 2020b).
In the patient selection domain, we considered two studies
(40%) to have low risk of bias (Dorman 2018; Piersimoni 2019);
and three studies to have high risk of bias: one study did not
report the manner of participant selection (Chakravorty 2017); one
study exclusively enrolled participants who had recently received
tuberculosis treatment (Mishra 2020b); and one study preselected
paucibacillary specimens (Wang 2019).
In the index test domain, we considered all studies (100%) to have
low risk of bias.
In the reference standard domain, we considered four studies (80%)
to have low risk of bias (Chakravorty 2017; Dorman 2018; Mishra
2020b; Piersimoni 2019), and one study to have unclear risk of bias
because information on blinding was not reported (Wang 2019).
In the flow and timing domain, we considered four studies (80%)
to have low risk of bias because all participants were included
in the analysis (Chakravorty 2017; Dorman 2018; Piersimoni 2019;
Wang 2019). We considered one study to have unclear risk of bias
because, in comparison with Xpert MTB/RIF, Xpert Ultra had a
higher number of rifampicin resistance indeterminate results which
were not included in the accuracy estimates (Mishra 2020b).
Findings
Of the total nine studies, seven (78%) were conducted in low-
or middle-income countries, and seven (78%) were mainly or
exclusively conducted in high tuberculosis burden countries. Seven
studies (78%) reported the HIV status of participants (Berhanu
2018; Dorman 2018; Mishra 2020a; Mishra 2020b; Pereira 2020;
Piersimoni 2019; Wang 2019), which ranged from 0%, Wang 2019,
to 62%, Berhanu 2018. Four studies (44%) evaluated only fresh
specimens (Berhanu 2018; Dorman 2018; Mishra 2020a; Pereira
2020); two studies (22%) evaluated only archived frozen samples
(Mishra 2020b; Piersimoni 2019); and three studies (33%) evaluated
both fresh and frozen specimens (Chakravorty 2017; Opota 2019;
Wang 2019). For the culture reference standard, one study used
only solid culture (Pereira 2020); five studies (56%) used only
liquid culture (Dorman 2018; Mishra 2020a; Mishra 2020b; Opota
2019; Piersimoni 2019); and three studies (33%) used both solid
and liquid cultures (Berhanu 2018; Chakravorty 2017; Wang 2019).
Key characteristics of the included studies are described in the
Characteristics of included studies table and Table 1.
I. Xpert Ultra versus Xpert MTB/RIF for the detection of
pulmonary tuberculosis
We identified seven studies that compared Xpert Ultra and Xpert
MTB/RIF in unselected participants against culture (Berhanu 2018;
Chakravorty 2017; Dorman 2018; Mishra 2020a; Opota 2019;
Pereira 2020; Piersimoni 2019). The median sample size was 239
(interquartile range (IQR) 217 to 272). The prevalence of pulmonary
tuberculosis in the studies ranged from 12.8% to 72.2%. The
sensitivity of Xpert Ultra ranged from 86% to 100%, and the
sensitivity of Xpert MTB/RIF from 81% to 100%. The specificity of
Xpert Ultra ranged from 89% to 99%, and the specificity of Xpert
MTB/RIF from 94% to 100% (Figure 5).
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Figure 5.   Forest plots of Xpert Ultra versus Xpert MTB/RIF sensitivity and specificity for pulmonary tuberculosis in
adults, unselected participants by reference standard. The squares represent the sensitivity and specificity of one
study, the black line its confidence interval (CI). TP = true positive; FP = false positive; FN = false negative; TN = true
negative
 
Xpert Ultra pooled sensitivity and specificity (95% CrI) were 90.9%
(86.2 to 94.7) and 95.6% (93.0 to 97.4) (2834 participants, 983
(34.7%) with tuberculosis); Xpert MTB/RIF pooled sensitivity and
specificity were 84.7% (78.6 to 89.9) and 98.4% (97.0 to 99.3) (2835
participants, 983 (34.7%) with tuberculosis) (Table 2). Piersimoni
2019 reported three non-determinate results for Xpert Ultra and
two for Xpert MTB/RIF, accounting for the small diLerence in the
total number of participants in this analysis. The diLerence in the
accuracy of Xpert Ultra minus Xpert MTB/RIF was estimated at 6.3%
(0.1 to 12.8) for sensitivity and −2.7% (−5.7 to −0.5) for specificity. We
estimated the probability that the pooled sensitivity of Xpert Ultra
exceeds that of Xpert MTB/RIF as 0.98. We estimated the probability
that the pooled specificity of Xpert Ultra was less than that of Xpert
MTB/RIF as 0.99 (Table 3).
Figure 6 presents the SROC plot for Xpert Ultra and Xpert MTB/
RIF pooled sensitivity and specificity estimates together with the
credible and prediction regions for pulmonary tuberculosis. The
summary point (pooled value) appears close to the upper leJ-hand
corner of the plots, suggesting high accuracy of both Xpert Ultra
and Xpert MTB/RIF for the detection of pulmonary tuberculosis.
The 95% credible regions around the summary points of sensitivity
and specificity, the regions that contain likely combinations of
the pooled sensitivity and specificity, are relatively narrow. The
95% prediction region is slightly wider for Xpert Ultra, displaying
more uncertainty as to where the likely values of sensitivity and
specificity might occur in a future study.
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Figure 6.   Summary plot of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity for the detection of pulmonary
tuberculosis. Each individual study is represented by a shaded circle. The size of the circle is proportional to the
sample size of the study such that larger studies are represented by larger circles. The filled circle is the median
pooled estimate for sensitivity and specificity, Xpert Ultra (red) and Xpert MTB/RIF (black). The dotted lines
represent the 95% credible region around the summary estimate; the dashed lines represent the 95% prediction
region. The range is truncated to consider only those regions of the receiver operator characteristic (ROC) space
where data have been observed.
 
We identified two studies that compared the accuracy of Xpert Ultra
and Xpert MTB/RIF against a composite reference standard based
on clinical and radiographic findings. In Berhanu 2018, Xpert Ultra
sensitivity and specificity (95% CI) were 80% (68 to 89) and 96% (92
to 98) versus Xpert MTB/RIF sensitivity and specificity of 72% (59
to 82) and 100% (98 to 100). In Opota 2019, Xpert Ultra sensitivity
and specificity (95% CI) were 96% (87 to 100) and 100% (97 to 100)
versus Xpert MTB/RIF sensitivity and specificity of 84% (71 to 93)
and 100% (97 to 100) (Figure 5).
Subgroup analyses
The results of the subgroup analyses by smear status, HIV status,
and history of tuberculosis are shown in Table 3.
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Xpert Ultra versus Xpert MTB/RIF in participants with smear-negative
sputum specimens
Seven studies reported data for participants with smear-negative
specimens (Figure 7) (Berhanu 2018; Chakravorty 2017; Dorman
2018; Mishra 2020a; Opota 2019; Piersimoni 2019; Wang 2019).
The sensitivity of Xpert Ultra ranged from 63% to 92%, and the
sensitivity of Xpert MTB/RIF from 41% to 77%. The lowest sensitivity
for Xpert Ultra (63%) was reported by Dorman 2018. This was
a multicentre study which took place in Belarus, Brazil, China,
Georgia, India, Kenya, South Africa, and Uganda, and assessed
Xpert Ultra accuracy based on a reference standard of multiple
cultures. The lowest sensitivity for Xpert MTB/RIF (41%) was
reported by Berhanu 2018. In this study, which took place in
South Africa, 62% of participants were HIV-positive. The specificity
of Xpert Ultra ranged from 71% to 99%. The lowest specificity
for Ultra (71%) was reported by Wang 2019, which preselected
smear-negative participants based on prior microscopy testing. The
specificity of Xpert MTB/RIF ranged from 78% to 100%, and the
lowest specificity (78%) was again reported by Wang 2019.
 
Figure 7.   Forest plots of Xpert Ultra versus Xpert MTB/RIF sensitivity and specificity for the detection of pulmonary
tuberculosis by smear status. The squares represent the sensitivity and specificity of one study, the black line its
confidence interval (CI). TP = true positive; FP = false positive; FN = false negative; TN = true negative
 
In a meta-analysis of studies with unselected participants
(excluding Wang 2019), Xpert Ultra pooled sensitivity was 77.5%
(67.6 to 85.6) and pooled specificity was 95.8% (92.9 to 97.7) (6
studies, 2049 participants). Xpert MTB/RIF pooled sensitivity and
specificity were 60.6% (48.4 to 71.7) and 98.8% (97.7 to 99.5) (6
studies, 2051 participants). The diLerence in the accuracy of Xpert
Ultra minus Xpert MTB/RIF was estimated at 16.7% (2.1 to 31.8) for
sensitivity and −3.0% (−5.9 to −0.9) for specificity. We estimated the
probability that the pooled sensitivity of Xpert Ultra exceeds that of
Xpert MTB/RIF as 0.99. We estimated the probability that the pooled
specificity of Xpert Ultra was less than that of Xpert MTB/RIF as 1.00.
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Repeating the meta-analysis including Wang 2019, Xpert Ultra
pooled sensitivity was slightly higher at 79.4% (70.2 to 87.0) and
specificity (95% CrI) slightly lower at 94.2% (88.3 to 97.5) (7 studies,
2547 participants); Xpert MTB/RIF pooled sensitivity and specificity
(95% CrI) were 63.0% (51.7 to 73.0) and 98.2% (94.9 to 99.6) (7
studies, 2549 participants).
Xpert Ultra versus Xpert MTB/RIF in participants with smear-positive
sputum specimens
Six studies reported data for participants with smear-positive
specimens (Figure 7) (Berhanu 2018; Chakravorty 2017; Dorman
2018; Mishra 2020a; Opota 2019; Piersimoni 2019). For both index
tests, sensitivity estimates were 97% or greater in all studies.
For smear-positive pulmonary tuberculosis, Xpert Ultra pooled
sensitivity (95% CrI) was 99.3% (98.1 to 99.8) (6 studies, 593
participants); Xpert MTB/RIF pooled sensitivity (95% CrI) was 98.9%
(97.5 to 99.6) (6 studies, 598 participants) (Table 3). We did not
determine pooled specificity because in four studies the value for
true negatives plus false positives was zero, and specificity was not
estimable (Berhanu 2018; Chakravorty 2017; Dorman 2018; Opota
2019). The diLerence in the accuracy of Xpert Ultra minus Xpert
MTB/RIF was estimated at 0.3% (−1.0 to 1.8) for sensitivity. We
estimated the probability that the pooled sensitivity of Xpert Ultra
exceeds that of Xpert MTB/RIF as 0.72.
Xpert Ultra versus Xpert MTB/RIF in people living with HIV
Three studies reported data in people living with HIV (Berhanu
2018; Dorman 2018; Mishra 2020a). The sensitivity of Xpert Ultra
ranged from 81% to 90%, and the sensitivity of Xpert MTB/RIF from
68% to 77%. The specificity of Xpert Ultra ranged from 78% to
96%; the specificity of Xpert MTB/RIF was higher, ranging from 99%
to 100% (Figure 8). Xpert Ultra pooled sensitivity and specificity
(95% CrI) were 87.6% (75.4 to 94.1) and 92.8% (82.3 to 97.0) (627
participants); Xpert MTB/RIF pooled sensitivity and specificity were
74.9% (58.7 to 86.2) and 99.7% (98.6 to 100.0) (635 participants)
(Table 4).
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Figure 8.   Forest plots of Xpert Ultra versus Xpert MTB/RIF sensitivity and specificity for the detection of pulmonary
tuberculosis by HIV status and history of tuberculosis. The squares represent the sensitivity and specificity of one
study, the black line its confidence interval (CI). TP = true positive; FP = false positive; FN = false negative; TN = true
negative
 
Xpert Ultra versus Xpert MTB/RIF in HIV-negative people
Three studies reported data for HIV-negative people (Berhanu 2018;
Dorman 2018; Mishra 2020a). The sensitivity of Xpert Ultra ranged
from 88% to 91%, and the sensitivity of Xpert MTB/RIF from 86%
to 90%. The specificity of Xpert Ultra ranged from 91% to 97%; the
specificity of Xpert MTB/RIF was higher, ranging from 97% to 100%
(Figure 8). Xpert Ultra pooled sensitivity and specificity (95% CrI)
were 90.3% (80.3 to 95.6) and 94.3% (79.8 to 98.7) (755 participants);
Xpert MTB/RIF pooled sensitivity and specificity (95% CrI) were
89.0% (78.3 to 94.8) and 98.1% (95.3 to 99.4) (755 participants)
(Table 4).
Xpert Ultra versus Xpert MTB/RIF in people with a history of
tuberculosis
Four studies reported data for people with a history of tuberculosis
(Berhanu 2018; Dorman 2018; Mishra 2020a; Mishra 2020b). The
sensitivity of Xpert Ultra ranged from 80% to 86%, and the
sensitivity of Xpert MTB/RIF from 70% to 92%. The specificity
of Xpert Ultra ranged from 69% to 97%, and the specificity of
Xpert MTB/RIF from 84% to 100% (Figure 8). The lowest specificity
(69% for Xpert Ultra) was reported by Mishra 2020b, which was
notable for preselecting patients who had previously received
antituberculosis treatment within the last two years. Xpert Ultra
pooled sensitivity and specificity (95% CrI) were 84.2% (72.5 to
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91.7) and 88.2% (70.5 to 96.6) (602 participants). Xpert MTB/RIF
pooled sensitivity and specificity (95% CrI) were 81.8% (68.7 to
90.0) and 97.4% (91.7 to 99.5) (610 participants). The diLerence in
the accuracy of Xpert Ultra minus Xpert MTB/RIF was estimated
at 2.4% (−11.9 to 17.2) for sensitivity and −8.9% (−27.0 to 0.6) for
specificity. We estimated the probability that the pooled sensitivity
of Xpert Ultra exceeds that of Xpert MTB/RIF as 0.64. We estimated
the probability that the pooled specificity of Xpert Ultra was less
than that of Xpert MTB/RIF as 0.97.
Repeating the meta-analysis excluding Mishra 2020b, Xpert Ultra
pooled sensitivity decreased to 83.3% (66.9 to 92.7), and specificity
increased to 91.5% (81.3 to 96.7) (3 studies, 434 participants).
Xpert MTB/RIF pooled sensitivity decreased to 76.6% (58.6 to 88.8),
and specificity increased to 99.0% (97.7 to 99.8) (3 studies, 432
participants).
Non-determinate results, detection of pulmonary tuberculosis
Regarding Xpert Ultra, six studies reported non-determinate results
for tuberculosis detection: 14/253 (5.5%) Mishra 2020a; 64/2001
(3.2%) Dorman 2018; 5/173 (2.9%) Mishra 2020b; 3/269 (1.1%)
Piersimoni 2019; 5/503 (1.0%) Wang 2019; 0/237 (0%) Berhanu
2018. Among six studies involving 3436 tests, the pooled proportion
of non-determinate test results for Xpert Ultra was low, at 2.0% (0.9
to 3.6).
Regarding Xpert MTB/RIF, five studies reported non-determinate
results for tuberculosis detection: 14/301 (4.6%) Mishra 2020a;
14/811 (1.7%) Wang 2019; 28/2001 (1.4%) Dorman 2018; 2/269
(0.7%) Piersimoni 2019; 1/179 (0.6%) Mishra 2020b. Among five
studies involving 3561 tests, the pooled proportion of non-
determinate test results for Xpert MTB/RIF was low, at 1.6% (0.8 to
3.0).
II. Detection of rifampicin resistance
Xpert Ultra versus Xpert MTB/RIF for the detection of rifampicin
resistance
We identified five studies that compared Xpert Ultra and Xpert MTB/
RIF accuracy for the detection of rifampicin resistance (Chakravorty
2017; Dorman 2018; Mishra 2020b; Piersimoni 2019; Wang 2019).
The median sample size was 107 (IQR 90 to 139). The prevalence
of rifampicin resistance in the studies ranged from 1.9% to 31.8%.
The sensitivity of Xpert Ultra ranged from 83% to 100%, and the
sensitivity of Xpert MTB/RIF from 93% to 100%. The specificity of
Xpert Ultra ranged from 98% to 100%, and the specificity of Xpert
MTB/RIF from 95% to 100% (Figure 9).
 
Figure 9.   Forest plot of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity for the detection of rifampicin
resistance. The squares represent the sensitivity and specificity of one study, the black line its confidence interval
(CI). TP = true positive; FP = false positive; FN = false negative; TN = true negative
 
Xpert Ultra pooled sensitivity and specificity were 94.9% (88.9 to
97.9) and 99.1% (97.7 to 99.8) (5 studies, 921 participants; high-
certainty evidence) versus Xpert MTB/RIF pooled sensitivity and
specificity of 95.3% (90.0 to 98.1) and 98.8% (97.2 to 99.6) (5 studies,
930 participants; high-certainty evidence) (Table 2). The pooled
sensitivity and specificity estimates for Xpert Ultra and Xpert MTB/
RIF were similar. The diLerence in the accuracy of Xpert Ultra minus
Xpert MTB/RIF was estimated at −0.3% (−6.9 to 5.7) for sensitivity
and 0.3% (−1.2 to 2.0) for specificity. We estimated the probability
that the pooled sensitivity of Xpert Ultra exceeds that of Xpert MTB/
RIF as 0.45. We estimated the probability that the pooled specificity
of Xpert Ultra was less than that of Xpert MTB/RIF as 0.33.
Figure 10 presents Xpert Ultra and Xpert MTB/RIF pooled sensitivity
and specificity estimates together with the credible and prediction
regions for rifampicin resistance. The summary point (pooled
value) appears close to the upper leJ-hand corner of the plots,
suggesting high accuracy of both Xpert Ultra and Xpert MTB/RIF for
the detection of rifampicin resistance. The 95% confidence regions
around the summary points of sensitivity and specificity, the
regions that contain likely combinations of the pooled sensitivity
and specificity, are relatively narrow. The 95% prediction regions,
the regions that contain the likely values of sensitivity and
specificity in a future study, are also relatively narrow.
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Figure 10.   Summary plot of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity for the detection of rifampicin
resistance. Each individual study is represented by a shaded circle. The size of the circle is proportional to the
sample size of the study such that larger studies are represented by larger circles. The filled circle is the median
pooled estimate for sensitivity and specificity, Xpert Ultra (red) and Xpert MTB/RIF (black). The dotted lines
represent the 95% credible region around the summary estimate; the dashed lines represent the 95% prediction
region. The range is truncated to consider only those regions of the receiver operator characteristic (ROC) space
where data have been observed.
 
Xpert Ultra versus Xpert MTB/RIF accuracy for the detection of
rifampicin resistance with respect to smear status
We identified four studies that compared Xpert Ultra and Xpert
MTB/RIF accuracy for rifampicin resistance detection by smear
status (Figure 11) (Chakravorty 2017; Dorman 2018; Mishra 2020b;
Piersimoni 2019).
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Figure 11.   Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity for the detection of rifampicin
resistance by smear status. The squares represent the sensitivity and specificity of one study, the black line its
confidence interval (CI). TP = true positive; FP = false positive; FN = false negative; TN = true negative
 
For smear-positive specimens, Xpert Ultra pooled sensitivity and
specificity were 93.9% (84.4 to 97.7) and 99.3% (97.8 to 99.9) (4
studies, 686 participants) versus Xpert MTB/RIF pooled sensitivity
and specificity of 95.5% (88.4 to 98.6) and 99.1% (97.3 to 99.9)
(4 studies, 699 participants). The pooled specificity estimates for
Xpert Ultra and Xpert MTB/RIF were similar. The diLerence in
the accuracy of Xpert Ultra minus Xpert MTB/RIF was estimated
at −1.5% (−10.9 to 6.0) for sensitivity and 0.1% (−1.5 to 2.0) for
specificity. We estimated the probability that the pooled sensitivity
of Xpert Ultra exceeds that of Xpert MTB/RIF as 0.32. We estimated
the probability that the pooled specificity of Xpert Ultra was less
than that of Xpert MTB/RIF as 0.41 (Table 3).
For smear-negative specimens, Xpert Ultra pooled sensitivity and
specificity were 92.0% (75.0 to 95.8) and 99.4% (96.2 to 100) (4
studies, 412 participants) versus Xpert MTB/RIF pooled sensitivity
and specificity of 95.4% (82.3 to 99.3) and 99.2% (94.8 to 100)
(4 studies, 416 participants). The pooled specificity estimates for
Xpert Ultra and Xpert MTB/RIF were similar. The diLerence in the
accuracy of Xpert Ultra minus Xpert MTB/RIF was estimated at
−3.1% (−20.7 to 11.7) for sensitivity and 0.1% (−3.0 to 4.5) for
specificity. We estimated the probability that the pooled sensitivity
of Xpert Ultra exceeds that of Xpert MTB/RIF as 0.30. We estimated
the probability that the pooled specificity of Xpert Ultra was less
than that of Xpert MTB/RIF as 0.42 (Table 3).
Indeterminate results, detection of rifampicin resistance
Regarding Xpert Ultra, four studies reported indeterminate results
for rifampicin resistance: 21/76 (27.6%) Mishra 2020b; 14/80 (17.5%)
Mishra 2020a; 16/684 (2.3%) Dorman 2018; 5/214 (2.3%) Wang 2019.
Among four studies involving 1054 tests, the pooled proportion of
indeterminate rifampicin resistance results for Xpert Ultra was 7.6%
(2.4 to 21.0). Importantly, two studies reported the number of trace
results that contributed to indeterminate rifampicin resistance
results. In both studies, all or almost all indeterminate results were
due to trace results, 13/14 (92.9%) in Mishra 2020a and 21/21 (100%)
in Mishra 2020b.
Regarding Xpert MTB/RIF, three studies reported indeterminate
results for rifampicin resistance: 1/61 (1.6%) Mishra 2020a; 1/67
(1.5%) Mishra 2020b; 4/684 (0.6%) Dorman 2018. Among three
studies involving 812 tests, the pooled proportion of indeterminate
test results for Xpert MTB/RIF was low, at 0.8% (0.2 to 2.4).
The estimated diLerence in the pooled proportion of indeterminate
rifampicin resistance results for Xpert Ultra versus Xpert MTB/RIF
was 6.7% (1.4 to 20.1). We estimated the probability that the pooled
proportion of indeterminate results for Xpert Ultra exceeds that for
Xpert MTB/RIF as 1.00.
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Xpert Ultra trace results
Summary of Xpert Ultra trace positive results
Eight studies reported the number of Xpert Ultra positive results
that were trace-positives (Berhanu 2018; Dorman 2018; Mishra
2020a; Mishra 2020b; Opota 2019; Pereira 2020; Piersimoni 2019;
Wang 2019). The percentage of trace-positive results ranged from
3.0% to 30.4% (Table 5). Among participants with trace-positive
results, four studies reported the percentage of participants with a
history of tuberculosis: 20% (10.3% trace) in Berhanu 2018, 57.9%
(7.1% trace) in Dorman 2018, 46.2% (18.6% trace) in Mishra 2020a,
and 100% (27.6% trace) in Mishra 2020b. Mishra 2020b recruited
participants with a recent history of tuberculosis (within the last
two years) (Table 5).
Xpert Ultra repeated test for diagnosing pulmonary tuberculosis
in people who have an initial Ultra trace result
We identified three studies where an Xpert Ultra repeated test
was used to diagnose pulmonary tuberculosis in people who
had an initial Ultra trace result, against culture: Mishra 2020a (4
participants), Piersimoni 2019 (4 participants), and Dorman 2018
(32 participants). Piersimoni 2019 retested the same initial samples.
Dorman 2018 retested on a separately collected sputum sample.
Mishra 2020a retested only those participants with discrepant
(Ultra trace-positive/culture-negative) results, and retesting was
performed on new specimens obtained a median of 444 days (range
245 to 526 days) aJer initial testing. Xpert Ultra accuracy of a second
(repeat) test in Mishra 2020a and Piersimoni 2019 was 100% for both
sensitivity and specificity. Dorman 2018 found sensitivity of 69%
(95% CI 39 to 91) and specificity of 47% (24 to 71) (Table 5, Figure
12).
 
Figure 12.   Forest plots of repeated Xpert Ultra sensitivity and specificity for detection of pulmonary tuberculosis in
adults with initial trace result, culture reference standard. The squares represent the sensitivity and specificity of




Three studies reported the number of NTMs that grew from
the specimens tested (total of 26 NTMs): Berhanu 2018 (4/244);
Piersimoni 2019 (15/269); and Wang 2019 (7/498). Only one of these
studies reported on Xpert Ultra and Xpert MTB/RIF results in those
with NTM (Piersimoni 2019), and found neither test was positive in
those who grew NTMs.
Sensitivity analyses
For Xpert Ultra for the detection of pulmonary tuberculosis, we
undertook sensitivity analyses by limiting inclusion in the meta-
analysis to the following.
• Studies where a single specimen yielded a single Xpert Ultra
result for a given participant. We excluded studies that included
more specimens than participants.
• Studies that only included untreated participants.
• Studies that used liquid culture as the reference standard.
• Studies where a consecutive or random sample of participants
was enrolled.
• Studies where the reference standard was blinded.
• Studies that only used fresh specimens.
For Xpert Ultra for the detection of pulmonary tuberculosis, these
sensitivity analyses made little diLerence to any of the findings
(Table 6). We planned to perform a sensitivity analysis for studies
that accounted for all participants in the analysis; however, for the
detection of pulmonary tuberculosis, this criterion was satisfied by
all studies.
D I S C U S S I O N
This Cochrane Review on the diagnostic accuracy of Xpert Ultra
compared to Xpert MTB/RIF for the detection of pulmonary
tuberculosis and rifampicin resistance in adults summarizes the
current literature. For the detection of pulmonary tuberculosis,
we identified nine studies, of which seven were conducted in
unselected participants. Estimation of accuracy in unselected
patients is consistent with the intended use of these tests. For the
detection of rifampicin resistance, we identified five studies.
Summary of main results
• For the detection of pulmonary tuberculosis, Xpert Ultra
sensitivity and specificity were 90.9% (86.2 to 94.7) and 95.6%
(93.0 to 97.4).
• For the detection of pulmonary tuberculosis, Xpert MTB/RIF
sensitivity and specificity were 84.7% (78.6 to 89.9) and 98.4%
(97.0 to 99.3).
• Xpert Ultra sensitivity and specificity were 77.5% (67.6 to 85.6)
and 95.8% (92.9 to 97.7) for smear-negative, culture-positive
tuberculosis.
• Xpert MTB/RIF sensitivity and specificity were 60.6% (48.4 to
71.7) and 98.8% (97.7 to 99.5) for smear-negative, culture-
positive tuberculosis.
• Xpert Ultra sensitivity and specificity for pulmonary tuberculosis
were 87.6% (75.4 to 94.1) and 92.8% (82.3 to 97.0) in people living
with HIV.
• Xpert MTB/RIF sensitivity and specificity for pulmonary
tuberculosis were 74.9% (58.7 to 86.2) and 99.7% (98.6 to 100) in
people living with HIV.
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• Xpert Ultra sensitivity and specificity for pulmonary tuberculosis
in people with a history of tuberculosis were 84.2% (72.5 to 91.7)
and 88.2 (70.5 to 96.6).
• Xpert MTB/RIF sensitivity and specificity for pulmonary
tuberculosis in people with a history of tuberculosis were 81.8%
(68.7 to 90.0) and 97.4% (91.7 to 99.5).
• For the detection of pulmonary tuberculosis, the pooled
proportion of Xpert Ultra non-determinate test results was low,
2.0% (0.9 to 3.6).
• For the detection of pulmonary tuberculosis, the pooled
proportion of Xpert MTB/RIF non-determinate test results was
low, 1.6% (0.8 to 3.0).
• For the detection of rifampicin resistance, Xpert Ultra sensitivity
and specificity were 94.9% (88.9 to 97.9) and 99.1% (97.7 to 99.8).
• For the detection of rifampicin resistance, Xpert MTB/RIF
sensitivity and specificity were 95.3% (90.0 to 98.1) and 98.8%
(97.2 to 99.6).
• For the detection of rifampicin resistance, the pooled proportion
of Xpert Ultra indeterminate test results was 7.6% (2.4 to 21.0).
• For the detection of rifampicin resistance, the pooled proportion
of Xpert MTB/RIF indeterminate test results was 0.8% (0.2 to 2.4).
Detection of pulmonary tuberculosis
If the point estimates for Xpert Ultra and Xpert MTB/RIF are applied
to a hypothetical cohort of 1000 people, where 10% of those
presenting with symptoms have pulmonary tuberculosis, Xpert
Ultra will miss 9 cases, and Xpert MTB/RIF will miss 15 cases. The
number of people wrongly diagnosed with pulmonary tuberculosis
would be 40 with Xpert Ultra and 14 with Xpert MTB/RIF (Summary
of findings 1).
Detection of rifampicin resistance
If the point estimates for Xpert Ultra and Xpert MTB/RIF are applied
to a hypothetical cohort of 1000 people, where 10% of those
presenting with symptoms have rifampicin resistance, Xpert Ultra
will miss 5 cases, and Xpert MTB/RIF will miss 5 cases. The number
of people wrongly diagnosed with rifampicin resistance would be 8
with Xpert Ultra and 11 with Xpert MTB/RIF (Summary of findings 2).
Xpert Ultra performance in diLerent subgroups
Xpert MTB/RIF detects DNA sequences of M tuberculosis aJer
amplification, and has a lower limit of detection of 131 CFUs/
mL (Helb 2010). The cycle threshold value (CT) is the number of
PCR cycles aJer which Xpert MTB/RIF probes successfully detect
M tuberculosis DNA in a given sample. Xpert MTB/RIF CT values
are strongly correlated with acid-fast bacillus (AFB) smear status
(Lange 2017). The lower sensitivity of Xpert MTB/RIF in individuals
with AFB smear-negative pulmonary tuberculosis is related to the
lower bacillary burden and higher associated CT value compared
to individuals with AFB smear-positive pulmonary tuberculosis.
Individuals with pulmonary tuberculosis and HIV co-infection are
more likely to have smear-negative tuberculosis, which implies a
lower bacillary burden and higher mean CT values on Xpert testing
(Beynon 2018; Lange 2017); this is the likely mechanism for the
lower sensitivity of Xpert Ultra for the diagnosis of tuberculosis in
people living with HIV.
Xpert Ultra was developed to improve sensitivity in the detection
of pulmonary tuberculosis, in particular in people with smear-
negative disease and people living with HIV. In smear-negative,
culture-positive pulmonary tuberculosis, we found Xpert Ultra
sensitivity of 77.5% as compared to Xpert MTB/RIF sensitivity of
60.6%; in people living with HIV, Xpert Ultra sensitivity was 87.6% as
compared to Xpert MTB/RIF sensitivity of 74.9%. The improvement
in Xpert Ultra sensitivity came at the expense of a slight reduction
in specificity as compared to Xpert MTB/RIF.
In individuals with a history of tuberculosis, we found that Xpert
Ultra pooled specificity (88.2%) was considerably lower than the
pooled specificity in the primary analysis (95.6%). Hence, the
increase in sensitivity of Xpert Ultra as compared to Xpert MTB/
RIF comes at the expense of specificity. Dorman and colleagues
found that specificity improved as time since the previous
diagnosis of tuberculosis increased, and approximated to that of
participants without a history of tuberculosis when elapsed time
was seven years (Dorman 2018). In comparison, for Xpert MTB/RIF
in individuals with a history of tuberculosis, we found that Xpert
MTB/RIF pooled specificity (97.4%) was only slightly lower than the
pooled specificity in the primary analysis (98.4%). Other studies
have reported that Xpert MTB/RIF may be positive at the end of
tuberculosis treatment despite cure (Friedrich 2013; Theron 2016;
Theron 2018), and may rarely remain positive for up to five years
aJer tuberculosis treatment (Boyles 2014).
Regarding the prevalence of tuberculosis, in comparing settings
with a higher or lower prevalence of tuberculosis, we previously
reported that for both Xpert MTB/RIF sensitivity and specificity,
the 95% CrIs in the two groups did not overlap, suggesting
an association of prevalence of tuberculosis with the accuracy
estimates (Horne 2019). In comparing settings with a higher or
lower prevalence of rifampicin resistance, we also previously
found that the Crls for specificity did not overlap, suggesting
an association of prevalence of rifampicin resistance with the
specificity estimates (Horne 2019). Changes in disease prevalence
have oJen been found to be associated with other important
changes, such as in the disease spectrum, which may aLect
diagnostic accuracy estimates (Leeflang 2013). In this review, we
did not analyse the eLect of tuberculosis prevalence on Xpert
Ultra accuracy. However, we acknowledge that as Xpert Ultra is
rolled out globally, diLerences in accuracy may have important
ramifications depending on the prevalence of tuberculosis and
rifampicin resistance (Kendall 2017).
For the detection of rifampicin resistance, Xpert Ultra and Xpert
MTB/RIF had similar sensitivity and specificity. Of interest, a recent
prospective population-based study in Rwanda, a country with
a low prevalence of rifampicin resistance, found that among
patients with rifampicin resistance on initial Xpert MTB/RIF testing,
47% (57/121) had a false-positive rifampicin resistance result, in
particular in specimens with a low tuberculosis bacillary burden
(Ngabonziza 2020). As mentioned above, in order to address
limitations in rifampicin resistance detection, Xpert Ultra uses
melting temperature-based analysis, in lieu of real-time PCR
analysis with Xpert MTB/RIF. Melting temperature-based analysis
allows Xpert Ultra to better distinguish resistance-conferring
mutations from silent mutations (Global Laboratory Initiative
2017).
To improve the sensitivity of Xpert Ultra, a new result category,
trace call, was added, which corresponds to the lowest bacillary
burden for M tuberculosis detection. The results of our systematic
review suggest that Xpert Ultra trace calls are not a rare finding.
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In the included studies, Xpert Ultra positive results that were
trace-positives ranged from 7% to 30%. Of interest, Dorman 2018
performed several post hoc analyses that evaluated the impact
of changing the classification of Xpert Ultra trace calls, which in
the primary analysis were considered positive for the identification
of M tuberculosis. Reclassifying all trace calls as a negative result
increased Xpert Ultra specificity and decreased its sensitivity. When
reclassifying trace calls as negative in participants with a history
of tuberculosis, or repeating trace calls with the second result
determining the ultimate classification, both resulted in sensitivity
estimates close to those observed in the primary analysis, with only
slightly compromised specificity.
We identified a higher number of rifampicin resistance
indeterminate results with Xpert Ultra (7.6%) compared to Xpert
MTB/RIF (0.8%). Notably, in studies that reported the number
of trace results that contributed to indeterminate rifampicin
resistance results, all, or almost all, Xpert Ultra indeterminate
rifampicin resistance results were due to trace-positive results:
92.9% in Mishra 2020a and 100% in Mishra 2020b. The
interpretation of and need for additional testing in patients
with trace results will depend on clinical and epidemiological
considerations.
We identified very limited data from patients who underwent
repeated Ultra testing aJer an initial trace-positive result. With
repeated testing against culture as the reference test, Dorman 2018
found Xpert Ultra sensitivity of 69% and specificity of 47% (32
participants), whereas Mishra 2020a (4 participants) and Piersimoni
2019 (4 participants) found Xpert Ultra sensitivity of 100% and
specificity of 100%. Based on the findings in Dorman 2018, WHO
recommended that "among persons without HIV infection with an
initial trace call positive result, a fresh specimen from the patient
should undergo repeat testing and the result of the second Ultra
test be used for clinical decisions" (WHO 2017). The issue of how
trace call results should be interpreted was recently reconsidered
by the WHO with the following guidance: “For patients with Xpert
Ultra trace results, decisions regarding treatment initiation should
include considerations of the clinical presentation and the patient
context (including prior treatment history, probability of relapse
and other test results)" (WHO Consolidated Guidelines (Module 3)
2020).
We summarized data for NTM separately by determining the per
cent of false-positive Xpert Ultra results in specimens that grew
NTMs. We found that among specimens that were culture-positive
for NTM, false-positive Xpert Ultra results did not occur. In an
analytical study, Chakravorty assessed in triplicate the specificity
of Xpert Ultra on 30 diLerent NTMs for cross-reactivity, and found
“MTB not detected” for all replicates tested (Chakravorty 2017).
We previously assessed whether Xpert MTB/RIF accuracy diLers
according to setting in which the test is performed, that is point of
care or peripheral settings compared with central and intermediate
laboratories (Horne 2019). Although we did not repeat this analysis
for Xpert Ultra (both index tests are run identically), we consider
it important to mention the findings from the previous review.
When comparing results from studies by test setting, we found the
pooled point estimates of Xpert MTB/RIF sensitivity and specificity
to be lower in peripheral settings than in central and intermediate
laboratories. However, there was considerable overlap in the
credible intervals of these estimates, and evidence is insuLicient
to suggest a diLerence in Xpert MTB/RIF accuracy by setting.
One of the confounding factors may be participant spectrum, the
direction of which we cannot predict with certainty (Horne 2019).
Of note, Theron and colleagues found no diLerence in Xpert MTB/
RIF accuracy when performed by trained nurses in a primary care
setting compared to performance by laboratory technicians at a
centralized facility (Theron 2014b).
Patient-important outcomes are especially relevant to patients,
decision-makers, and the wider tuberculosis community. We are
not aware of direct evidence of the eLect of Xpert Ultra on
patient outcomes; however, two meta-analyses of the impact
of Xpert MTB/RIF compared the eLect of Xpert MTB/RIF and
smear microscopy on all-cause mortality. Di Tanna and colleagues
summarized the accuracy of Xpert MTB/RIF in an individual patient-
level data meta-analysis (3 trials, 8143 participants) (Di Tanna
2019), and Haraka and colleagues performed a systematic review
and meta-analysis (5 trials, 10,409 participants) (Haraka 2018;
WHO Consolidated Guidelines (Module 3) 2020). In both analyses,
Xpert MTB/RIF did not show a statistically significant eLect on
all-cause mortality, though the direction of eLect was towards
mortality reduction. These findings require careful interpretation,
as the lack of statistical significance of impact of Xpert MTB/RIF on
mortality may not indicate a lack of impact, but rather a lack of
evidence of a diLerence (Altman 1995; Greenland 2016). InsuLicient
power to detect mortality in randomized trials measuring the
impact of diagnostic tests on patient-important outcomes has been
previously discussed as a limitation of such trials (Di Tanna 2019;
Schumacher 2019). Early detection of tuberculosis and rifampicin
resistance may not lead to improved patient outcomes if the test
result is not linked to appropriate treatment and other healthcare
services (Pai 2018).
In a systematic review of economic evaluations (28 studies),
Zwerling and colleagues summarized costs, cost-eLectiveness,
and aLordability of molecular tests for tuberculosis, including
Xpert MTB/RIF, Xpert Ultra, and Truenat (Molbio Diagnostics, Goa,
India). Most studies evaluated Xpert MTB/RIF; no studies evaluated
Xpert Ultra; and one study evaluated Truenat (WHO Consolidated
Guidelines (Module 3) 2020). Variations in costing, eLectiveness,
and epidemiological parameters were present in the included
studies, making direct comparisons across studies challenging. The
review found that the cost-eLectiveness of Xpert MTB/RIF improved
among populations with higher tuberculosis and HIV prevalence
and in settings where rates of empirical tuberculosis treatment
were low. Cost-eLectiveness of Xpert MTB/RIF is dependent
on a number of factors, including placement of GeneXpert
machines (in centralized or decentralized facilities), testing volume,
tuberculosis prevalence, level of empirical tuberculosis treatment,
and pretreatment loss to follow-up (WHO Consolidated Guidelines
(Module 3) 2020).
AJer the WHO recommended the use of Xpert MTB/RIF, country-
level uptake was rapid. A 2018 survey of market penetration of Xpert
MTB/RIF in high tuberculosis burden countries found greater use
of Xpert MTB/RIF compared to smear microscopy for tuberculosis
diagnosis (Cazabon 2018). There are currently no publications
regarding market penetration of Xpert Ultra, which only requires
new cartridges and a soJware update to existing GeneXpert
machines. However, by the end of 2019, over 80 countries had
procured Xpert Ultra tests. In more than 20 of these countries,
Xpert Ultra conversion from MTB/RIF was greater than 90%.
Examples of countries fully converted to Xpert Ultra are Eswatini
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(high TB/HIV burden country); Lesotho (high tuberculosis burden
and high TB/HIV burden country); Morocco; South Africa (high
tuberculosis burden, high TB/HIV burden, high MDR-TB burden
country); Uganda (high TB/HIV burden country); Ukraine (high MDR-
TB burden country); and Zimbabwe (high tuberculosis burden, high
TB/HIV burden, high MDR-TB burden country) (Denamps 2020 [pers
comm]).
This review represents the most comprehensive review of the
diagnostic accuracy of Xpert Ultra, including comparative accuracy
studies of Xpert Ultra and Xpert MTB/RIF. Regarding Xpert
MTB/RIF, previous reviews have provided additional findings
(Horne 2019; Steingart 2014). These reviews provide evidence
that may help countries make decisions about scaling up the
tests for programmatic management of tuberculosis and drug-
resistant tuberculosis. Although the information in this review
will help inform such decisions, other factors such as resource
requirements and feasibility (including stable electrical power
supply, temperature control, and maintenance of the cartridge
modules) will also be important considerations.
Application of the meta-analysis to a hypothetical cohort
Summary of findings 1 and Summary of findings 2 summarize
the findings of our review by applying the results to a
hypothetical cohort of 1000 individuals with presumptive
pulmonary tuberculosis or rifampicin resistance. We have
presented several diLerent scenarios. For Xpert Ultra and Xpert
MTB/RIF for the detection of pulmonary tuberculosis, we used
prevalences of tuberculosis of 2.5%, 10%, and 30%. For the
detection of rifampicin resistance, we used prevalences of
rifampicin resistance of 2%, 10%, and 15% (5% is estimated
to be equivalent to the upper limit for rifampicin resistance
prevalence in new cases; 15% is estimated to be the lower limit for
rifampicin resistance prevalence among previously treated cases).
The consequences of false-positive results are patient anxiety,
morbidity from additional testing and unnecessary treatment, and
possible delay in further diagnostic evaluation. The consequences
of false-negative results are increased risk of patient morbidity
and mortality, and continued risk of community transmission of
tuberculosis.
Strengths and weaknesses of the review
Completeness of evidence
The findings in this review are based on comprehensive searching,
strict inclusion criteria, and standardized data extraction. We had
repeated correspondence with study authors to obtain additional
data and missing information. The search strategy included studies
published in all languages. Although we may have missed some
studies despite the comprehensive search, we think it is unlikely
that the findings would have changed. We followed the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses of
Diagnostic Test Accuracy (PRISMA-DTA) (McInnes 2018).
Accuracy of the reference standards used
Culture is regarded as the best available reference standard for
active tuberculosis disease and was the reference standard for
tuberculosis in this review (Lewinsohn 2017). We considered the
type of culture used in the included studies because liquid culture
is more sensitive than solid culture (American Thoracic Society
2000). Most studies did use liquid culture or a combination of solid
and liquid culture; only one of the total nine studies exclusively
used solid culture. For the culture reference standard, one study
used only solid culture (Pereira 2020); five studies (56%) used only
liquid culture (Dorman 2018; Mishra 2020a; Mishra 2020b; Opota
2019; Piersimoni 2019); and three studies (33%) used both solid and
liquid cultures (Berhanu 2018; Chakravorty 2017; Wang 2019).
Phenotypic culture-based DST methods using WHO-recommended
critical concentrations and line probe assays, WHO-recommended
tests (WHO Consolidated Guidelines (Module 3) 2020), were
the reference standards for rifampicin resistance. Regarding
phenotypic culture-based DST, following completion of this
review, the WHO published recommendations lowering critical
concentrations for rifampicin resistance testing (MGIT and 7H10)
to reduce misclassification of false resistance (WHO 2021). We will
incorporate the new recommendations in future updates of this
review. In this review, two of the total five studies used line probe
assays (i.e. MTBDRplus) alone as the reference standard.
We assessed the number of specimens with NTMs that were Xpert
Ultra- and Xpert MTB/RIF-positive. Three studies reported a total
of 26 NTMs that grew from the specimens tested. Only one of
these studies reported on Xpert Ultra and Xpert MTB/RIF results
in those with NTM (Piersimoni 2019), and found neither test was
positive in those that grew NTMs. In the previous review, among 10
studies that reported information comprising 141 NTM, Xpert MTB/
RIF was negative in all specimens (Horne 2019). Similarly, a study
that assessed Xpert Ultra specificity using 20 culture-positive NTM
specimens (covering a total of 18 species) found that Xpert Ultra
was negative for all specimens (Perez-Risco 2018).
Quality of the included studies
Most studies used consecutive selection of participants and
interpreted the reference standard results without knowledge of
index test results. Xpert Ultra and MTB/RIF results are generated
automatically, without requiring subjective interpretation. For
pulmonary tuberculosis detection, using QUADAS-C, for patient
selection, six studies had low risk of bias. We considered three
studies to have high risk of bias: one study did not report
the manner of participant selection (Chakravorty 2017); one
study exclusively enrolled participants who had recently received
tuberculosis treatment (Mishra 2020b); and one study exclusively
enrolled smear-negative participants (Wang 2019). In general,
studies were fairly well reported, although we corresponded with
authors for additional data and missing information. We encourage
the authors of future studies to follow the recommendations in the
STARD (Standards for Reporting of Diagnostic Accuracy) statement
to improve the quality of reporting (Bossuyt 2015).
Interpretability of subgroup analyses
We investigated potential sources of heterogeneity in diLerent
subgroups. For tuberculosis detection, Xpert Ultra had higher
sensitivity in smear-positive and HIV-negative participants.
Importantly, we found Xpert Ultra to have higher sensitivity and
lower specificity than Xpert MTB/RIF in smear-negative participants
and people living with HIV, two subgroups in which Xpert MTB/
RIF has suboptimal sensitivity. In individuals with a history of
tuberculosis, we found that Xpert Ultra pooled specificity was
considerably lower than the pooled specificity in the primary
analysis. Hence, the increase in sensitivity of Xpert Ultra as
compared to Xpert MTB/RIF comes at the expense of specificity.
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As there were small numbers of studies in these analyses, results
should be interpreted with caution.
Comparison with other systematic reviews
We are aware of one previously published systematic review that
estimated the diagnostic accuracy of Xpert Ultra for pulmonary
tuberculosis and rifampicin resistance in adults (Zhang 2019). For
the detection of pulmonary tuberculosis, this review found pooled
sensitivity of 88.5% (95% CI 82.1 to 92.9) and specificity of 96.7%
(95% CI 95.1 to 97.8), similar to the findings of our review (pooled
sensitivity 90.9%, 95% CrI 86.2 to 94.7 and pooled specificity 95.6%,
95% CrI 93.0 to 97.4). For the detection of rifampicin resistance,
Xpert Ultra accuracy estimates were also similar to those in our
review. Another study included adults and children and assessed
Xpert Ultra and Xpert MTB/RIF performance in both pulmonary and
extrapulmonary tuberculosis (Jiang 2020). We identified several
systematic reviews on the diagnostic accuracy of Xpert MTB/RIF,
which are summarized in Table 7.
Compared with previous systematic reviews, our review had a more
recent search date thus increasing the number of potential studies
for inclusion. Our strict inclusion criteria, for example including only
studies that used culture as the reference standard and excluding
case-control studies, meant that some studies included in other
reviews were excluded from our review.
Completeness and relevance of the review
Our review included studies using all four previous generations
of Xpert MTB/RIF (G1, G2, G3, G4 cartridges) and the newest
version, Xpert Ultra. We have included studies that compared
the accuracy of Xpert Ultra and Xpert MTB/RIF for diagnosing
pulmonary tuberculosis and rifampicin resistance. Our review,
plus information previously reported in Horne 2019, present
a reasonably complete assessment of the accuracy of these
tests. A Cochrane Review on Xpert MTB/RIF for extrapulmonary
tuberculosis (including 11 studies evaluating Xpert Ultra) was
published (Kohli 2021). This review found that in people with
presumptive extrapulmonary tuberculosis, Xpert Ultra and Xpert
MTB/RIF may be helpful in confirming the diagnosis. Test sensitivity
varied across diLerent extrapulmonary specimens, while for most
specimens specificity was high. In addition, Xpert Ultra and Xpert
MTB/RIF had similar accuracy for the detection of rifampicin
resistance (Kohli 2021). A Cochrane Review update on Xpert MTB/
RIF and Xpert Ultra for extrapulmonary tuberculosis is under way.
A Cochrane Review on Xpert MTB/RIF and Xpert Ultra for active
tuberculosis (pulmonary and extrapulmonary) in children was
recently published (Kay 2020).
Applicability of findings to the review question
For the detection of pulmonary tuberculosis, we had low concern
for most studies in the index test and reference standard domains.
In the patient selection domain, we considered only four studies
(44%) to have low concern because participants in these studies
were evaluated in primary care facilities, local hospitals, or both
settings consistent with the intended use of the test. For the
detection of rifampicin resistance, we also had low concern for
all QUADAS-2 domains except for patient selection, where we
considered only one of five studies to have low concern for
applicability.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
For diagnosing pulmonary tuberculosis, we found Xpert Ultra to
have higher sensitivity and lower specificity than Xpert MTB/RIF,
especially in smear-negative participants and people living with
HIV. Xpert Ultra specificity was lower than that of Xpert MTB/
RIF in participants with a history of tuberculosis. The sensitivity
and specificity trade-oL would be expected to vary by setting.
For the detection of rifampicin resistance, Xpert Ultra and Xpert
MTB/RIF had similar sensitivity and specificity. Ultra trace-positive
results were common. For patients with Xpert Ultra trace-positive
results, decisions regarding treatment initiation should include
considerations of the clinical presentation and the patient context
(including prior treatment history, probability of relapse, and other
test results). Xpert Ultra and Xpert MTB/RIF provide accurate results
and can allow rapid initiation of treatment for rifampicin-resistant
and multidrug-resistant tuberculosis.
Implications for research
Future studies should assess the diagnostic accuracy of Xpert
Ultra compared with other rapid tests for tuberculosis and
drug resistance, especially in diLicult-to-diagnose groups, that is
children, people living with HIV, and those with extrapulmonary
tuberculosis. Understanding the impact of Xpert Ultra in settings
with diLering prevalence of tuberculosis, in people with a history
of tuberculosis, with varying strategies for the classification of
trace calls, and its impact on people-important outcomes will be
important. The ongoing use of Xpert Ultra or Xpert MTB/RIF in
tuberculosis programmes in high tuberculosis burden settings, as
well as their use in primary care clinics, where the test provides the
opportunity to begin treatment promptly, will contribute evidence
on whether their use leads to improvements in patient health.
There is an urgent need for studies that investigate strategies for
responding to Ultra trace-positive results. Operational research
is needed to ensure that tests are optimally used in settings of
intended use.
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Characteristics of included studies [ordered by study ID]
 
Study characteristics
Patient Sampling Cohort, all participants received Xpert MTB/RIF, and
the order by which participants were selected to re-
ceive Xpert Ultra was randomized, prospective
Patient characteristics and setting Presenting signs and symptoms: adults (18 years old)
who presented with at least 1 TB symptom, which in-
cluded cough of any duration, fever, weight loss, and
night sweats
Age: median 36 years (range 18 to 77)
Sex, female: 33%
HIV infection: 62%





World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 27%
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Index tests Xpert MTB/RIF and Xpert Ultra
Target condition and reference standard(s) Pulmonary tuberculosis











Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
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Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results for TB detection interpreted without
knowledge of the results of the index test?
Yes    
Were the reference standard results for rifampicin resistance detection in-
terpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, manner of participant selection not
reported, retrospective for FIND biobank specimens,
prospective for clinical specimens; paired design,
Xpert Ultra was tested retrospectively on a frozen
aliquot of the fresh sputum specimen originally tested
with Xpert MTB/RIF
Patient characteristics and setting Presenting signs and symptoms: participants present-
ing with symptoms compatible with TB
Age: adult
Sex, female: not reported
HIV infection: not reported
History of TB: not reported
Sample size: 277
Chakravorty 2017 
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Clinical setting: not reported
Laboratory level: central
Country: FIND biobank frozen specimens (Peru, Viet-
nam, South Africa) and clinical specimens (Georgia,
India)
World Bank Income Classification: middle and low
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 72%
Index tests Xpert MTB/RIF and Xpert Ultra
Target condition and reference standard(s) Pulmonary tuberculosis




Flow and timing  
Comparative  
Notes 212 frozen specimens were included from FIND
biobank. Ultra was tested retrospectively on a frozen





Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
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If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results for TB detection interpreted without
knowledge of the results of the index test?
Yes    
Were the reference standard results for rifampicin resistance detection in-
terpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cohort, consecutive enrolment, prospective data col-
lection, multicentre study, paired design with Xpert
Dorman 2018 
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Ultra and Xpert MTB/RIF tested on the same sputum
sample
Patient characteristics and setting Presenting signs and symptoms: presumed pul-
monary TB
Age: adults, median 28 years (IQR 28 to 50)
Sex, female: 40%
HIV infection: 44%
History of TB: 21%
Sample size: 1439 for detection of Mycobacterium tu-
berculosis, 551 for rifampicin resistance
Clinical setting: both outpatient and inpatient
Laboratory level: central (reference)
Country: Belarus, Brazil, China, Georgia, India, Kenya,
South Africa, Uganda
World Bank Income Classification: low and middle in-
come
High TB burden country: yes (Brazil, China, India,
Kenya, South Africa)
High MDR-TB burden country: yes (Belarus, China, In-
dia, Kenya, South Africa)
High TB/HIV burden country: yes (Brazil, China, India,
Kenya, South Africa, Uganda)
Prevalence of TB cases in the study: 32%
Index tests Xpert MTB/RIF and Xpert Ultra





Flow and timing  
Comparative  
Notes 25 participants (3%) who were smear-positive but in





Risk of bias Applicability
concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Unclear    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results for TB detection interpreted without
knowledge of the results of the index test?
Yes    
Were the reference standard results for rifampicin resistance detection in-
terpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
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Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? No    





Patient Sampling Cohort, consecutive, prospective. Paired design; col-
lected 3 sputum samples from each patient, 2 at the
first visit, of which 1 was tested using Xpert and the
other was tested using culture, and 1 sample the next
morning, which was tested using Ultra
Patient characteristics and setting Presenting signs and symptoms: presumptive pul-
monary TB according to the WHO
Age: ≥ 18 years; median 37 years (IQR 27 to 50)
Sex, female: 49%
HIV infection: 20%





World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 30%
Index tests Xpert MTB/RIF and Xpert Ultra
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Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results for TB detection interpreted without
knowledge of the results of the index test?
Yes    
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Were the reference standard results for rifampicin resistance detection in-
terpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, random selection (1:1 testing Xpert
Ultra or Xpert MTB/RIF), prospective
Patient characteristics and setting Presenting signs and symptoms: preselected for re-
cent (< 2 years) previous TB treatment
Age: ≥ 18 years; median 37.5 (30 to 50)
Sex, female: 40%
HIV infection: 44%





World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 26%
Index tests Xpert MTB/RIF OR Xpert Ultra
Target condition and reference standard(s) Pulmonary tuberculosis
Mishra 2020b 
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Flow and timing Of 124 participants tested with Xpert Ultra, 18 were ri-
fampicin resistant indeterminate; of 127 participants







Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? No    
Could the selection of patients have introduced bias?   High risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
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Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results for TB detection interpreted without
knowledge of the results of the index test?
Yes    
Were the reference standard results for rifampicin resistance detection in-
terpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective and retro-
spective; Xpert MTB/RIF assay was tested on some
fresh and some frozen specimens, whereas Xpert Ul-
tra was performed only on frozen specimens paired
with Xpert MTB/RIF
Patient characteristics and setting Presenting signs and symptoms: suspected pul-
monary tuberculosis
Age: unknown
Sex, female: not reported
HIV infection: not reported
History of TB: not reported
Sample size: 196
Clinical setting: laboratory-based evaluation in a hos-
pital using the index test for decisions regarding the
need for airborne isolation
Opota 2019 
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Laboratory level: central
Country: Switzerland
World Bank Income Classification: high
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 24%
Index tests Xpert MTB/RIF and Xpert Ultra
Target condition and reference standard(s) Pulmonary tuberculosis





Flow and timing  
Comparative  
Notes Study included 69 frozen specimens. When consider-
ing the 47 culture-positive specimens, all of the iso-




Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Opota 2019  (Continued)
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Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results for TB detection interpreted without
knowledge of the results of the index test?
Yes    
Were the reference standard results for rifampicin resistance detection in-
terpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective; paired de-
sign, all samples were tested with Xpert Ultra and
Xpert MTB/RIF
Pereira 2020 
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Patient characteristics and setting Presenting signs and symptoms: respiratory symp-
toms suggestive of pulmonary tuberculosis, such as
productive cough for > 2 weeks, cough of any duration
accompanied by constitutional symptoms (fever for
at least 3 days, night sweats or weight loss of at least 3
kg in the previous month), or haemoptysis
Age: > 18 years; mean 50 years (SD 18)
Sex, female: 44%
HIV infection: 2%





World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: no
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 13%
Index tests Xpert MTB/RIF and Xpert Ultra
Target condition and reference standard(s) Pulmonary tuberculosis
Ogawa-Kudoh method
Speciation: not reported






Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
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Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results for TB detection interpreted without
knowledge of the results of the index test?
Unclear    
Were the reference standard results for rifampicin resistance detection in-
terpreted without knowledge of the results of the index test?
     
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Pereira 2020  (Continued)
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Study characteristics
Patient Sampling Cross-sectional, consecutive, retrospective, frozen
specimens; paired design, Xpert Ultra was tested on a
frozen aliquot of the fresh sputum specimen originally
tested with Xpert MTB/RIF
Patient characteristics and setting Presenting signs and symptoms: patients present-
ing with tuberculosis symptoms and abnormal X-ray
imaging
Age: median 42 years (range 7 to 91, with only 2/254
participants below 15 years)
Sex, female: 37%
HIV infection: not reported
History of TB: excluded from study
Sample size: 266
Clinical setting: tertiary hospital (majority were inpa-
tients, < 10% outpatients)
Laboratory level: central
Country: Italy
World Bank Income Classification: high
High TB burden country: no
High MDR-TB burden country: no
High TB/HIV burden country: no
Prevalence of TB cases in the study: 46%
Index tests Xpert MTB/RIF and Xpert Ultra











Risk of bias Applicability
concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results for TB detection interpreted without
knowledge of the results of the index test?
Yes    
Were the reference standard results for rifampicin resistance detection in-
terpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
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Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cohort, consecutive, prospective; paired design, Xpert
Ultra assay was tested on frozen specimens and Xpert
MTB/RIF on fresh specimens
Patient characteristics and setting Presenting signs and symptoms: patients with tuber-
culosis symptoms suspected of having pulmonary tu-
berculosis, smear-negative




History of TB: 50%
Sample size: 498




World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study: 24%
Index tests Xpert MTB/RIF and Xpert Ultra
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Flow and timing  
Comparative  





Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? No    
Could the selection of patients have introduced bias?   High risk  
Are there concerns that the included patients and setting do not match
the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results for TB detection interpreted without
knowledge of the results of the index test?
Unclear    
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Were the reference standard results for rifampicin resistance detection in-
terpreted without knowledge of the results of the index test?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Wang 2019  (Continued)
Abbreviations: ICU: intensive care unit; IQR: interquartile range; LJ: Löwenstein–Jensen; MDR-TB: multidrug-resistant TB; MGIT:
Mycobacteria Growth Indicator Tube; MODS: microscopic observation drug susceptibility; SD: standard deviation; TB: tuberculosis; WHO:
World Health Organization
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Abong 2019 Xpert Ultra not evaluated
Acuna-Villaorduna 2017 Duplicate data with additional analyses; Boum 2016 includes same data set
Ade 2016 Includes both adults and children, or no information about age of enrolment
Adelman 2014 Abstract
Afshan 2019 Xpert Ultra not evaluated
Agizew 2017 Data insufficient for 2 x 2 table
Agizew 2019 Xpert Ultra not evaluated
Agrawal 2016 Includes both adults and children, or no information about age of enrolment
Agustina 2019 Paediatric population
Ai 2019 Xpert Ultra not evaluated
Akhter 2019 Xpert Ultra not evaluated
Alame-Emane 2017 Data insufficient for 2 x 2 table
Al-Ateah 2012 Includes both adults and children, or no information about age of enrolment
Albay 2016 Includes both adults and children, or no information about age of enrolment
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Study Reason for exclusion
Al-Darraji 2016 Data insufficient for 2 x 2 table
Allahyartorkaman 2019 Xpert Ultra not evaluated
Alland 2015 Abstract
Alnimr 2014 Data insufficient for 2 x 2 table
Alvarez 2015 Includes both adults and children, or no information about age
Alvarez-Uria 2012 Reference standard not satisfied
Alvis-Zakzuk 2017 Systematic review
Andriani 2016 Abstract
Antonenka 2013 Case-control study
Ardizzoni 2019 Xpert Ultra not evaluated
Aricha 2019 Xpert Ultra not evaluated
Armand 2011 This was a case-control study that compared Xpert MTB/RIF with an in-house IS6110-based re-
al-time PCR using TaqMan probes (IS6110-TaqMan assay) for TB detection.
Asencio 2013 Cost-effectiveness study
Aston 2016 Abstract
Atashi 2017 Data insufficient for 2 x 2 table
Atehortua 2015 Includes both adults and children, or no information about age of enrolment
Atuhumuza 2016 Abstract
Atwine 2015 Data insufficient for 2 x 2 table
Auld 2016 Includes both adults and children
Aurin 2014 Includes both adults and children, or no information about age of enrolment
Avashia 2016 Reference standard not satisfied
Ayala 2016 Data insufficient for 2 x 2 table
Aydemir 2019 Xpert Ultra not evaluated
Bablishvili 2015 Includes both adults and children, or no information about age of enrolment
Badal-Faesen 2017 Duplicate data with additional analyses; Luetkemeyer 2016 includes same data set
Baikunje 2019 Xpert Ultra not evaluated
Bajrami 2016 Includes data for pulmonary and extrapulmonary TB combined
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Study Reason for exclusion
Balcha 2014 Xpert was not the index test.
Banu 2014 Data insufficient for 2 x 2 table
Barcellini 2019 Community-based screening
Barkham 2016 Abstract
Barnard 2012 Includes both adults and children, or no information about age of enrolment
Bates 2013 This study evaluated Xpert MTB/RIF for the diagnosis of TB in children.
Benjamin 2019 Xpert Ultra not evaluated
Bhardwaj 2019 Xpert Ultra not evaluated
Biadglegne 2014 Includes both adults and children, or no information about age of enrolment
Bilgin 2016 Includes both adults and children, or no information about age of enrolment
Bimba 2019 Xpert Ultra not evaluated
Bisognin 2018 Not a diagnostic accuracy study
Bjerrum 2015 Xpert was not the index test.
Boakye-Appiah 2016 Data insufficient for 2 x 2 table
Bojang 2016 Xpert was not the index test.
Bonnet 2017 Data insufficient for 2 x 2 table
Borodulina 2019 Xpert Ultra not evaluated
Boum 2016 Xpert Ultra not evaluated
Bowles 2011 Includes both adults and children, or no information about age of enrolment
Bunsow 2014 Includes respiratory specimens and gastric aspirates
Byashalira 2019 Xpert Ultra not evaluated
Capocci 2016 Abstract
Causse 2011 This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB.
Cavanaugh 2016 Data insufficient for 2 x 2 table
Cayci 2017 Includes both adults and children, or no information about age of enrolment
Celik 2015 Includes both adults and children, or no information about age of enrolment
Chakraborty 2019 Xpert Ultra not evaluated
Chhajed 2019 Xpert Ultra not evaluated
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Study Reason for exclusion
Chishty 2016 Abstract
CiJçi 2011 Includes both adults and children, or no information about age of enrolment
Clouse 2012 Study on patient impact
Cross 2014 Reference standard not satisfied
Cross 2015 Includes both adults and children, or no information about age of enrolment
Dagnra 2015 Data insufficient for 2 x 2 table
Dahale 2019 Xpert Ultra not evaluated
Daum 2015 Xpert not the index test
Deggim 2013 Includes both adults and children, or no information about age of enrolment
Dierberg 2016 Data insufficient for 2 x 2 table
Dorjee 2012 Case report
Dorman 2012 Prevalence survey
Dowdy 2011 Cost-effectiveness study
Eldin 2019 Xpert Ultra not evaluated
Elzein 2019 Xpert Ultra not evaluated
Fantahun 2019 Xpert Ultra not evaluated
Feasey 2013 Data insufficient for 2 x 2 table
Fernandez 2017 Abstract
FIND 2011 This study compared Xpert MTB/RIF G3 and G4. We excluded it owing to concerns about duplicate
data. In addition, the criteria for the reference standard for rifampicin resistance detection were
not satisfied.
Fong 2017 Abstract
Friedrich 2011 This study evaluated Xpert MTB/RIF for the diagnosis of pleural TB.
Gama de Andrade 2017 Abstract
Garcia-Basteiro 2019 Inappropriate reference standard
Gati 2018 Xpert Ultra not evaluated
Gelalcha 2017 Includes both adults and children, or no information about age of enrolment
Gounder 2014 Includes both adults and children, or no information about age of enrolment
Griesel 2016 Abstract
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Study Reason for exclusion
Griesel 2017 Includes data for pulmonary and extrapulmonary TB combined
Guenaoui 2016 Includes both adults and children, or no information about age of enrolment
Gupta 2014 Abstract
Gurbanova 2016 Abstract
Gurbanova 2017 Includes data for pulmonary and extrapulmonary TB combined
Gursoy 2016 Includes both adults and children, or no information about age of enrolment
Habeenzu 2017 Includes both adults and children, or no information about age of enrolment
Hai 2019 Xpert Ultra not evaluated
Hanifa 2016 Reference standard not satisfied
Heidebrecht 2016 Data insufficient for 2 x 2 table
Hillemann 2011 This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB.
Hiza 2017 Not a diagnostic accuracy study
Ho 2016 Community-based screening
Hodille 2019 Only culture-positive specimens were tested; Xpert MTB/RIF was not evaluated.
Horo 2017 Includes both adults and children, or no information about age of enrolment
Hu 2014 Includes both adults and children, or no information about age of enrolment
Huang 2018 Includes both adults and children, or no information about age of enrolment
Huerga 2017 Xpert was not the index test.
Ioannidis 2010 We could not obtain this article.
Ioannidis 2011 Includes both adults and children, or no information about age of enrolment
Iram 2015 Includes both adults and children, or no information about age of enrolment
Jafari 2013 Data insufficient for 2 x 2 table
Jin 2019 Xpert Ultra not evaluated
Jing 2017 Includes both adults and children, or no information about age of enrolment
Jipa 2016 Abstract
Jones-Lopez 2014 Xpert was not the index test.
Kang 2016 Abstract
Kaur 2016 Systematic review
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Study Reason for exclusion
Kayigire 2013 Not a diagnostic accuracy study
Kazemian 2019 Xpert Ultra not evaluated
Kelly-Cirino 2017 Xpert was not the index test.
Kendall 2019 Case-control study
Kerkhoff 2013 Data insufficient for 2 x 2 table
Kerkhoff 2014 Data insufficient for 2 x 2 table
Khadka 2019 Xpert Ultra not evaluated
Khalil 2015 Includes both adults and children, or no information about age of enrolment
Khan 2016 Data insufficient for 2 x 2 table
Kim 2012 Case-control study
Kim CH 2014 Duplicate data; Kim CH 2015 includes the same data with more participants
Kim CH 2015 Xpert Ultra not evaluated
Kim MJ 2015 Data insufficient for 2 x 2 table
Kim YW 2015 Includes both adults and children, or no information about age of enrolment
Kolia-Diafouka 2019 Case-control study
Lange 2017 Systematic review
Laskar 2017 Could not obtain full text
Lawn 2012a Study on patient impact
Lawn 2012b Data insufficient for 2 x 2 table
Lawn 2012c Primarily a lipoarabinomannan detection study
Lawn 2013 Data insufficient for 2 x 2 table
Lawn 2015 Reference standard not satisfied
Lawn 2017 Reference standard not satisfied
Lebina 2016 Community-based screening
Lessells 2017 Impact study
Li 2016 Includes both adults and children, or no information about age of enrolment
Li 2017 Systematic review
Li 2020 Xpert Ultra not evaluated
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Study Reason for exclusion
Ligthelm 2011 This study evaluated Xpert MTB/RIF for the diagnosis of TB lymphadenitis.
Lombardi 2017 Includes both adults and children, or no information about age of enrolment
Luetkemeyer 2016 Xpert Ultra not evaluated
Mafort 2017 Abstract
Malbruny 2011 Includes both adults and children, or no information about age of enrolment
Marlowe 2011 Includes both adults and children, or no information about age of enrolment
Matabane 2015 Includes both adults and children, or no information about age of enrolment
Mave 2017 Screening
Maynard-Smith 2014 Systematic review
Mechal 2019 Xpert Ultra not evaluated
Miller 2011 Includes both adults and children, or no information about age of enrolment
Miotto 2012 Treatment monitoring
Mntonintshi 2017 Data insufficient for 2 x 2 table
Modi 2016 Xpert was not the index test.
Mokaddas 2016 Abstract
More 2017 Data insufficient for 2 x 2 table
Morozova 2016 Abstract
Moure 2012 This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB.
Mukherjee 2017 Reference standard not satisfied
Mulder 2017 Xpert was not the index test.
Muñoz 2013 Study on patient impact
Myneedu 2014 Includes both adults and children, or no information about age of enrolment
Naidoo 2016 Data insufficient for 2 x 2 table
Narasimooloo 2012 Study on patient impact
Ng 2018 Case-control study
Nguyen 2018 Includes both adults and children, or no information about age of enrolment
Ngwira 2017 Abstract
Nhu 2013 This study evaluated Xpert MTB/RIF for the diagnosis of TB in children.
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Study Reason for exclusion
Nicol 2011 This study evaluated Xpert for the diagnosis of TB in children.
Ninan 2016 Xpert was not the index test.
Nosova 2013a Duplicate data; same study as Nosova 2013b. Nosova 2013a is written in Russian.
Nosova 2013b Xpert Ultra not evaluated
Ntinginya 2012 Active case finding, not a diagnostic test accuracy study
O'Grady 2012 This study evaluated Xpert MTB/RIF in patients able to produce sputum, irrespective of admission
diagnosis, not presumed TB patients.
Oliveira 2019 Xpert Ultra not evaluated
Omar 2019 Xpert Ultra not evaluated
Omrani 2014 Not a diagnostic accuracy study
Opota 2016 Includes both adults and children, or no information about age of enrolment
Osman 2014 Case-control study
Ou 2015 Includes both adults and children, or no information about age of enrolment
Ozkutuk 2014 Includes both adults and children, or no information about age of enrolment
Pandey P 2017 Includes both adults and children, or no information about age of enrolment
Pandey S 2017 Includes both adults and children, or no information about age of enrolment
Parcell 2017 Includes both adults and children, or no information about age of enrolment
Patel 2020 Xpert Ultra not evaluated
Patil 2014 Case report
Patil 2017 Reference standard not satisfied
Peter 2012 This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB.
Peter 2013 Data insufficient for 2 x 2 table
Peter 2015 Duplicate data; study was nested in Theron 2014b
Qureshi 2019 Xpert Ultra not evaluated
Rachow 2012 This study evaluated Xpert for the diagnosis of TB in children.
Rahman 2016 Not a diagnostic accuracy study
Raizada 2015 Not a diagnostic accuracy study
Ramamurthy 2016 Data insufficient for 2 x 2 table
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Study Reason for exclusion
Ramirez 2014 Not a diagnostic accuracy study
Rasheed 2019 Xpert Ultra not evaluated
Rathish 2019 Xpert Ultra not evaluated
Rathour 2019 Xpert Ultra not evaluated
Reechaipichitkul 2016 Duplicate data; more participants were included in Reechaipichitkul 2017
Reechaipichitkul 2017 Xpert Ultra not evaluated
Reed 2016 Xpert was not the index test.
Rees 2018 Impact study
Reis 2019 Xpert Ultra not evaluated
Rivera 2019 Xpert Ultra not evaluated
Rossato 2018 Study design unclear, possibly case-control
Rufai 2014 Data insufficient for 2 x 2 table
Ruiz 2017 Xpert was not the index test.
Sachdeva 2015 Not a diagnostic accuracy study
Saeed 2017 Data insufficient for 2 x 2 table
Sanchez-Padilla 2015 Not a diagnostic accuracy study
Sauzullo 2016 Includes both adults and children, or no information about age of enrolment
Schutz 2019 Xpert Ultra not evaluated
Set 2019 Xpert Ultra not evaluated
Shah 2014 Case-control study
Shah 2020 Xpert Ultra not evaluated
Sharma 2019 Did not include specimen of choice
Shenai 2013 Data insufficient for 2 x 2 table
Shenoy 2019 Xpert Ultra not evaluated
Shilpa 2017 Reference standard not satisfied
Simone 2019 Xpert Ultra not evaluated
Singh 2019 Xpert Ultra not evaluated
Smith 2014 Not a diagnostic accuracy study
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Study Reason for exclusion
Somashekar 2014 Reference standard not satisfied
Somily 2016 Includes both pulmonary and extrapulmonary specimens combined
Strydom 2015 Case-control study
Sumalani 2019 Xpert Ultra not evaluated
Sumayya 2019 Xpert Ultra not evaluated
Sun 2019 Paediatric population
Sureshbabu 2016 Reference standard not satisfied
Tadesse 2016 Abstract
Tahseen 2016 Drug resistance survey
Tahseen 2019 Xpert Ultra not evaluated
Talib 2019 Xpert Ultra not evaluated
Tan 2017 Xpert was not the index test.
Taylor 2012 This study evaluated Xpert for the diagnosis of extrapulmonary TB.
Teo 2011 Includes both adults and children, or no information about age of enrolment
Theron 2012 Treatment monitoring
Theron 2014a Duplicate data set for Theron 2014a with a different aim
Theron 2016 Duplicate data. Author reported that this study overlaps with Theron 2014a and can be excluded.
Theron 2018 Screening study
Thibbadee 2016 Abstract
Thit 2017 Xpert was not the index test.
To 2017 Abstract
Tortoli 2012 This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB.
Uddin 2019 Xpert Ultra not evaluated
Udgirkar 2019 Xpert Ultra not evaluated
Ullah 2016 Includes both adults and children, or no information about age of enrolment
Ullah 2017 Includes both adults and children, or no information about age of enrolment
Vadwai 2011 This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB.
Van Kampen 2015 Includes both adults and children, or no information about age of enrolment
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Study Reason for exclusion
Van Rie 2011 Case report
Walters 2012 This study evaluated Xpert MTB/RIF for the diagnosis of TB in children.
Walusimbi 2013 Systematic review
Wang 2015 Systematic review
Wang 2016 Includes both adults and children, or no information about age of enrolment
Williamson 2012 Case-control study
Wood 2012 This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB.
Xie 2017 Xpert was not the index test.
Yadav 2017 Includes both adults and children, or no information about age of enrolment
Yan 2016 Systematic review
Yang X 2020 Xpert Ultra not evaluated
Yeong 2019 Xpert Ultra not evaluated
Yu 2020 Xpert Ultra not evaluated
Zar 2012 This study evaluated Xpert MTB/RIF for the diagnosis of TB in children.
Zar 2019 This study evaluated Xpert MTB/RIF for the diagnosis of TB in children.
Zemlyansky 2016 Includes both adults and children, or no information about age of enrolment
Zhou 2020 Xpert Ultra not evaluated
Zimba 2019 Xpert Ultra not evaluated
Zurcher 2019 Xpert Ultra not evaluated
PCR: polymerase chain reaction; TB: tuberculosis
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous bronchoalveolar lavage fluid in HIV-in-
fected adults: a prospective cohort study
Target condition and refer-
ence standard(s)
Tuberculosis, HIV/AIDS
Index and comparator tests Index test is Xpert MTB/RIF Ultra on bronchoalveolar lavage fluid in HIV-positive patients. Compara-
tor tests will include Xpert MTB/RIF and culture.
Starting date 5 February 2018
ChiCTR180001479 
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Contact information Yang Zhou; 516472422@qq.com




Study name Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous bronchoalveolar lavage fluid in
HIV-infected adults: a prospective cohort study
Target condition and reference
standard(s)
Tuberculosis and HIV/AIDS, MGIT (Mycobacteria Growth Indicator Tube)
Index and comparator tests Xpert Ultra
Starting date 12 February 2018
Contact information Peize Zhang; 516472422@qq.com




Study name The diagnostic value of medical thoracoscopy combined with Xpert MTB/RIF Ultra in smear and
culture negative pulmonary tuberculosis
Target condition and refer-
ence standard(s)
Tuberculosis (smear and culture negative)
Index and comparator tests Index tests are Xpert MTB/RIF Ultra and thoracoscopy with comparator of pathologic diagnosis in
smear and culture-negative pulmonary tuberculosis.
Starting date 12 October 2019
Contact information Hairong Huang; huanghairong@tb123.org




Study name Evaluation of GeneXpert Ultra and digital chest radiography for diagnosing tuberculosis
Target condition and refer-
ence standard(s)
Tuberculosis, HIV/AIDS
Index and comparator tests Index test is Xpert Ultra with comparator of Xpert or microscopy (current standard of care), with
reference standard of bacteriologically confirmed TB.
Starting date 9 February 2019
Contact information Dr Marriot Nliwasa; mnliwasa@medcol.mw
ISRCTN77241966 
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Study name A trial of same-day testing and treatment to improve outcomes among symptomatic patients new-
ly diagnosed with HIV
Target condition and refer-
ence standard(s)
Tuberculosis, HIV/AIDS
Index and comparator tests Spot and early-morning Xpert Ultra results and chest X-ray, as single and as combined tests, with
liquid culture as reference standard
Starting date 16 May 2017
Contact information Serena P Koenig, MD; skoenig@bwh.harvard.edu




Study name Xpert Ultra and Xpert HIV-VL in people living with HIV (UltraHIV)
Target condition and reference standard(s) Tuberculosis, HIV/AIDS
Index and comparator tests Impact study
Starting date 15 June 2017
Contact information Grant Theron, PhD; gtheron@sun.ac.za




Study name Improving tuberculosis diagnosis and treatment through Basic, Applied and health systems Re-
search (BAR)
Target condition and reference
standard(s)
Tuberculosis
Index and comparator tests Xpert Ultra point-of-care testing compared to the standard-of-care tuberculosis testing at a cen-
tralized facility
Starting date 29 November 2017
Contact information Grant Theron, PhD; gtheron@sun.ac.za
Notes ClinicalTrials.gov Identifier: NCT03356925
NCT03356925 
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Study name Achieving tuberculosis control in Zambia
Target condition and reference
standard(s)
Tuberculosis
Index and comparator tests Comparison of 2 diagnostic tools (chest X-ray with computer-assisted diagnosis versus C-reactive
protein) and Xpert Ultra for active community-based tuberculosis case detection
Starting date 13 April 2018
Contact information Stewart Reid, MD, MPH; stewart.reid@cidrz.org




Study name Xpert MTB/XDR Clinical Evaluation Trial
Target condition and reference stan-
dard(s)
Tuberculosis, MDR-TB, Xpert MTB/XDR
Index and comparator tests Index test is Xpert MTB/XDR, with comparators of Xpert MTB/RIF or Ultra.
Starting date 2 November 2018
Contact information Adam Penn-Nicholson, PhD; adam.penn-nicholson@finddx.org




Study name Evaluation of CRISPR-based test for the rapid identification of TB in pulmonary tuberculosis sus-
pects
Target condition and refer-
ence standard(s)
Tuberculosis, CRISPR
Index and comparator tests Index test is CRISPR, with reference standard and comparators to include Xpert MTB/RIF, clinical di-
agnosis, and culture.
Starting date 30 August 2019
Contact information Wenhong Zhang; zhangwenhong@fudan.edu.cn
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Study name POC Strategies to Improve TB Care in Advanced HIV Disease (TBPOC)
Target condition and refer-
ence standard(s)
Tuberculosis, HIV/AIDS
Index and comparator tests Index test is Lateral flow urine lipoarabinomannan (LF-LAM), with comparators including sputum
smear microscopy, Xpert MTB/RIF and Xpert MTB/RIF Ultra, and sputum culture.
Starting date 10 October 2019
Contact information Johanna Maria Åhsberg, MD; johanna.maria.aahsberg@rsyd.dk




Study name Tuberculosis Research of INA-RESPOND On Drug Resistance (TRIPOD)
Target condition and reference
standard(s)
Tuberculosis
Index and comparator tests Index test is Xpert MTB/RIF and acid-fast bacilli (AFB) smear as compared to sputum culture. Will
also evaluate clinical diagnosis as compared to sputum culture.
Starting date 5 May 2016
Contact information Erlina Burhan, SpP(K), MSc




D A T A
Presented below are all the data for all of the tests entered into the review.
 
Table Tests.   Data tables by test
Test No. of studies No. of participants
1 Xpert Ultra for detection of pulmonary TB 9 3500
2 Xpert MTB/RIF for detection of pulmonary TB 7 2835
3 Xpert Ultra for detection of pulmonary TB, composite reference standard 2 433
4 Xpert MTB/RIF for detection of pulmonary TB, composite reference standard 2 433
5 Smear-negative, Xpert Ultra, culture 7 2547
6 Smear-negative, Xpert MTB/RIF, culture 7 2549
Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary
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Test No. of studies No. of participants
7 Smear-positive, Xpert Ultra 6 593
8 Smear-positive, Xpert MTB/RIF 6 598
9 HIV-positive, Xpert Ultra 3 627
10 HIV-positive, Xpert MTB/RIF 3 635
11 HIV-negative, Xpert Ultra 3 755
12 HIV-negative, Xpert MTB/RIF 3 755
13 Xpert Ultra, history of TB 4 602
14 Xpert Ultra, no history of TB 3 1476
15 Xpert MTB/RIF, history of TB 4 610
16 Xpert MTB/RIF, no history of TB 3 1476
17 Xpert Ultra for detection of rifampicin resistance 5 921
18 Xpert MTB/RIF for detection of rifampicin resistance 5 930
19 Xpert Ultra repeated test in adults with initial trace result, microbiological refer-
ence standard
3 40
20 Xpert Ultra for detection of rifampicin resistance, smear-positive 4 686
21 Xpert MTB/RIF for detection of rifampicin resistance, smear-positive 4 699
22 Xpert Ultra for detection of rifampicin resistance, smear-negative 4 412
23 Xpert MTB/RIF for detection of rifampicin resistance, smear-negative 4 416
 
 
Test 1.   Xpert Ultra for detection of pulmonary TB
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Test 2.   Xpert MTB/RIF for detection of pulmonary TB
 
 
Test 3.   Xpert Ultra for detection of pulmonary TB, composite reference standard
 
 
Test 4.   Xpert MTB/RIF for detection of pulmonary TB, composite reference standard
 
 
Test 5.   Smear-negative, Xpert Ultra, culture
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Test 6.   Smear-negative, Xpert MTB/RIF, culture
 
 
Test 7.   Smear-positive, Xpert Ultra
 
 
Test 8.   Smear-positive, Xpert MTB/RIF
 
 
Test 9.   HIV-positive, Xpert Ultra
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Test 10.   HIV-positive, Xpert MTB/RIF
 
 
Test 11.   HIV-negative, Xpert Ultra
 
 
Test 12.   HIV-negative, Xpert MTB/RIF
 
 
Test 13.   Xpert Ultra, history of TB
 
 
Test 14.   Xpert Ultra, no history of TB
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Test 15.   Xpert MTB/RIF, history of TB
 
 
Test 16.   Xpert MTB/RIF, no history of TB
 
 
Test 17.   Xpert Ultra for detection of rifampicin resistance
 
 
Test 18.   Xpert MTB/RIF for detection of rifampicin resistance
 
 
Test 19.   Xpert Ultra repeated test in adults with initial trace result, microbiological reference standard
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Test 20.   Xpert Ultra for detection of rifampicin resistance, smear-positive
 
 
Test 21.   Xpert MTB/RIF for detection of rifampicin resistance, smear-positive
 
 
Test 22.   Xpert Ultra for detection of rifampicin resistance, smear-negative
 
 
Test 23.   Xpert MTB/RIF for detection of rifampicin resistance, smear-negative
 
 
A D D I T I O N A L   T A B L E S
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LJ and MGIT LJ and MGIT
Dorman 2018 Belarus, Brazil, China,
Georgia, India, Kenya,
South Africa, Uganda






28 40% 44% 21% LJ and MGIT LJ and MGIT
Mishra 2020a South Africa Prospective cohort 239 37 49% 20% 39% MGIT MTBDRplus
Mishra 2020b South Africa Cross-sectional 346 38 40% 44% 100% MGIT MTBDRplus











Pereira 2020 Brazil Cross-sectional 180 50 44% 2% 0% Ogawa-Kudoh N/A
Piersimoni
2019
Italy Cross-sectional 266 42 37% Not re-
ported
Excluded MGIT MGIT
Wang 2019 China Prospective cohort 498 47 34% 0% 50% LJ and MGIT LJ
Table 1.   Summary of key study characteristics 



































































































































































































































Xpert Ultra, unselected partici-
pants* (pulmonary tuberculosis
detection)








Xpert MTB/RIF (pulmonary tuber-
culosis detection)
































Table 2.   Xpert Ultra and Xpert MTB/RIF for the detection of pulmonary tuberculosis and rifampicin resistance 
Abbreviations: CrI: credible interval; DST: drug susceptibility testing with solid or liquid culture methods
* Positive and negative predictive values were determined at a pretest probability of 10%
**This analysis included studies that did not preselect participants based on microcopy results or those who had received previous antituberculosis treatment.
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Detection of pulmonary tuberculosis
Test (studies, participants) Xpert Ultra (7, 2834) Xpert MTB/RIF (7,
2835)





Sensitivity (95% CrI) 90.9% (86.2 to 94.7) 84.7% (78.6 to 89.9) 6.3% (0.1 to 12.8) 0.98
Specificity (95% CrI) 95.6% (93.0 to 97.4) 98.4% (97.0 to 99.3) −2.7% (−5.7 to −0.5) 0.01
Smear-positive (tuberculosis detection)





Sensitivity (95% CrI) 99.3% (98.1 to 99.8) 98.9% (97.5 to 99.6) 0.3% (−1.0 to 1.8) 0.72
Specificity (95% CrI) Not estimated Not estimated N/A N/A
Smear-negative (tuberculosis detection)
Test (studies, participants) Xpert Ultra (6, 2049) Xpert MTB/RIF (6,
2051)





Sensitivity (95% CrI) 77.5% (67.6 to 85.6) 60.6% (48.4 to 71.7) 16.7% (2.1 to 31.8) 1.00
Specificity (95% CrI) 95.8% (92.9 to 97.7) 98.8% (97.7 to 99.5) −3.0% (-5.9 to −0.9) 0.00
History of tuberculosis





Sensitivity (95% CrI) 84.2% (72.5 to 91.7) 81.8% (68.7 to 90.0) 2.4% (−11.9 to 17.2) 0.64
Specificity (95% CrI) 88.2% (70.5 to 96.6) 97.4% (91.7 to 99.5) −8.9% (−27.0 to 0.6) 0.03
Detection of rifampicin resistance





Sensitivity (95% CrI) 94.9% (88.9 to 97.9) 95.3% (90.0 to 98.1) −0.3% (−6.9 to 5.7) 0.45
Specificity (95% CrI) 99.1% (97.7 to 99.8) 98.8% (97.2 to 99.6) 0.3% (−1.2 to 2.0) 0.67
Smear-positive (rifampicin resistance detection)





Table 3.   Comparative accuracy of Xpert Ultra and Xpert MTB/RIF* 
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Sensitivity (95% CrI) 93.9% (84.4 to 97.7) 95.5% (88.4 to 98.6) −1.5% (−10.9 to 6.0) 0.32
Specificity (95% CrI) 99.3% (97.8 to 99.9) 99.1% (97.3 to 99.9) 0.1% (−1.5 to 2.0) 0.59
Smear-negative (rifampicin resistance detection)





Sensitivity (95% CrI) 92.0% (75.0 to 95.8) 95.4% (82.3 to 99.3) −3.1% (−20.7 to 11.7) 0.30
Specificity (95% CrI) 99.4% (96.2 to 100) 99.2% (94.8 to 100) 0.1% (−3.0 to 4.5) 0.58
Table 3.   Comparative accuracy of Xpert Ultra and Xpert MTB/RIF*  (Continued)
Abbreviations: CrI: credible interval
* We determined absolute diLerences for sensitivity and specificity when there were at least four studies in a subgroup.
** Slight diLerences in numerical values are likely due to rounding errors.
 
 





































3 (635) 74.9% (58.7 to 86.2) 99.7% (98.6 to 100.0) 96.3% (85.4 to 99.6) 97.3% (95.6 to 98.5)
Table 4.   Xpert Ultra and Xpert MTB/RIF accuracy, analyses in HIV-positive and HIV-negative people 
Abbreviations: CI: confidence interval; CrI: credible interval
* Positive and negative predictive values were determined at a pretest probability of 10%
 
Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary
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on trace results (not
including retesting)
Trace results repeated?




at day 60 in 1 partici-


























tive, a follow-up cul-
ture at 2 months was
positive in 2/10.
Yes: 13 of the retested samples were
culture+; of these 9 were Ultra + on re-
peat. 19 of the samples were culture-, of
which 10 were Ultra false +
Mishra 2020a South Africa 72/239 13 (18.6%) 6/13 (46.2%) 4/13 - Yes: new sample collected median 444
days, after the initial testing. 4 samples
retested (1 culture+, 3 culture-); all cul-
ture- were not detected, and culture+
was Ultra +
Mishra 2020b South Africa 44/168 21 (27.6%) 21/21 (100%) 2/21 - No
Opota 2019 Switzerland 47/196 5 (10.0%) Not reported 4/5 The 1 culture-nega-





Pereira 2020 Brazil 157/180 1 (3.0%) Not reported Not reported - No













































































































































































































Italy 123/266 8 (6.7%) Excluded from
study
5/8 - Yes: 4 respiratory samples retested (1
culture+, 3 culture-); all culture- were
not detected, and culture+ was Ultra +
Wang 2019 China 117/498 65 (30.4%) Not reported Not reported - No
Table 5.   Summary of Xpert Ultra trace-positive results  (Continued)
Abbreviations: FIND: Foundation for Innovative New Diagnostics; MGIT: Mycobacteria Growth Indicator Tube; MTB: Mycobacterium tuberculosis; TB: tuberculosis
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Xpert Ultra sensitivity and specificity for pulmonary tuberculo-









Studies that only included untreated participants (exclude
studies with some percentage of participants who were re-









Studies that used liquid culture only as the reference standard



































Table 6.   Sensitivity analyses, Xpert Ultra 
Abbreviations: Crl: credible interval.
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15 (2046) Xpert MTB/RIF 67% (62 to 71) 98% (97 to 99) N/A N/A N/A
Steingart 2014 December
2013




95% (90 to 97) 98% (97 to 99)
Yan 2016 Not report-
ed
12 (8122) Xpert MTB/RIF 89% (87 to 90) 98% (98 to 99) N/A N/A N/A
Li 2017 June
2015
24 (2486) Xpert MTB/RIF 87% (83 to 90) 97% (96 to 98) N/A N/A N/A
Alvis-Zakzuk 2017 December
2015






85 (41,965) Xpert MTB/RIF 85% (82 to 87) 98% (97 to 98) 48 (8020) 96% (94 to 97) 98% (98 to 99)




89% (82 to 94) 97% (95 to 98) 4 (856) 95% (92 to 97) 99% (98 to 100)










97% (96 to 98)
N/A N/A N/A
Table 7.   Selected systematic reviews on the diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF for pulmonary tuberculosis and rifampicin
resistance 











































































































































































































*Summary sensitivity and specificity estimates are provided for Xpert MTB/RIF, except for Zhang 2019 and Jiang 2020, which evaluated Xpert Ultra.
Chang 2012 included adults and children; Xpert MTB/RIF for detection of rifampicin resistance, sensitivity range 17% to 100%, specificity range 72% to 100%.
Walusimbi 2013 only included smear-negative participants.
Steingart 2014 is a previous Cochrane Review.
Yan 2016 only included studies that provided data by smear and HIV status.
Li 2017 106 studies (52,410 specimens) for both pulmonary and extrapulmonary tuberculosis.
Alvis-Zakzuk 2017 summarized accuracy of Xpert MTB/RIF for the detection of rifampicin resistance, sensitivity range 33% to 100%, specificity range 91% to 100%.
Horne 2019 is a previous Cochrane Review update.
Zhang 2019 included adults and children.
Jiang 2020 included adults and children, and assessed Xpert Ultra and Xpert MTB/RIF accuracy for the detection of both pulmonary and extrapulmonary tuberculosis.
Systematic reviews not included in this table:
Kaur 2016 did not provide summary sensitivity and specificity estimates.
Lange 2017 provided sensitivity and specificity with respect to Xpert cycle threshold (CT) values.
Maynard-Smith 2014 provided accuracy estimates for pulmonary tuberculosis on gastric aspirates and stool.
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Protocol section Refreshed protocol
Background and research
question
This review update will describe the burden of pulmonary tuberculosis worldwide based on the lat-
est World Health Organization (WHO) Global Tuberculosis Report. The Background will describe
the updated WHO guidelines on molecular methods for diagnosing tuberculosis, including Xpert
MTB/RIF and Xpert Ultra. The WHO Meeting to update the guidelines will take place 3 to 6 Decem-
ber 2019. This Cochrane Review update will have informed these guidelines.
Inclusion criteria This is a diagnostic test accuracy review. Participants, index tests, and target condition will be the
same as in Horne 2019. We will add a composite reference standard for Xpert Ultra defined as cul-
ture or clinical criteria as defined by the primary study authors, or both.
The primary objectives are to assess the diagnostic accuracy of Xpert Ultra for the diagnosis of
pulmonary tuberculosis and to assess the diagnostic accuracy of Xpert Ultra for the diagnosis ri-
fampicin resistance in adults.
Secondary objectives are as follows:
• to investigate potential sources of heterogeneity in test accuracy, including history of tuberculosis
and smear and HIV status;
• to compare the accuracy of Xpert Ultra and Xpert MTB/RIF in studies that evaluated both tests.
Concerning patient outcomes, the Discussion will summarize and refer to key findings in the test-
treatment Cochrane Review by Haraka 2018.
Methods We will use QUADAS-2 to appraise methodological quality of the included studies, consistent with
Horne 2019.
If there are sufficient data, we will perform meta-analyses using a bivariate random-effects model.
The analyses will include:
• Xpert Ultra for pulmonary tuberculosis, culture reference standard;
• Xpert Ultra for pulmonary tuberculosis, composite reference standard;
• accuracy of Xpert Ultra versus Xpert MTB/RIF in studies that evaluated both tests;
• Xpert Ultra for pulmonary tuberculosis, smear-positive;
• Xpert Ultra for pulmonary tuberculosis, smear-negative, culture positive;
• Xpert Ultra for pulmonary tuberculosis, HIV-positive;
• Xpert Ultra for pulmonary tuberculosis in participants with a history of tuberculosis;
• Xpert Ultra for detecting rifampicin resistance.
We will create 'Summary of findings' tables for the two primary objectives of the review.
Table 8.   Prespecified changes for 2021 review update* 
*This table was approved by the Cochrane Infectious Diseases Group editorial team on 23 October 2019.
 
 
A P P E N D I C E S
Appendix 1. Search strategy
MEDLINE (OVID) and Embase (OVID)
1. (tuberculosis or TB).tw
limit 1 to yr="2007 -Current"
2. Mycobacterium tuberculosis/
limit 2 to yr="2007 -Current"
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3. Tuberculosis, Multidrug-Resistant/ or Tuberculosis/ or Tuberculosis, Pulmonary/
limit 3 to yr="2007 -Current"
4.  1 or 2 or 3
5. (Xpert or GeneXpert or cepheid or( near* patient)). tw.
limit 4 to yr="2007 -Current"
4 and 5
Web of Knowledge (SCI-expanded, SSCI, Conference Proceedings science, BIOSIS previews)
 (tuberculosis OR TB OR mycobacterium) (topic) AND (Xpert OR Genexpert OR cepheid) (topic)
LILACS
(tuberculosis OR TB OR mycobacterium) (Words) AND (xpert OR Genexpert OR Cepheid) (Words)
SCOPUS
(tuberculosis OR TB OR mycobacterium) (title, abstract, keywords) AND (xpert OR Genexpert OR Cepheid) (title, abstract, keywords)
Appendix 2. Data extraction form
 
I. ID
ID substudy (for study centres: a, b, c, etc.)  
First author  
Corresponding author and email  




Year (of publication)  
Year (study start date)  




Country where study was conducted  
Country World Bank Classification 1 – Low income
2 - Middle income
3 – High income
4 - Low and high income
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5 - Low and middle income
6 - Low, middle, and high
7 – Other combination, describe
Purpose of testing as described in the study 1 - Diagnosis
2 - Screening in HIV-positive people
9 - Could not tell
Study states:
Objective of study 1 - Detection of PTB only
2 - Detection of rifampicin resistance only
3 - Both, detection of PTB and rifampicin resistance
Study design 1 – Randomized controlled trial
2 – Cross-sectional
3 – Cohort
4 – Other, specify
9 – Could not tell
If other, describe:
IIa. Questions about preselection during enrolment
Were patients preselected based upon microscopy results? 1 - Yes
2 - No
9 - Unknown/NR
If yes, what was the basis for preselection? 1 - Primarily or exclusively smear positive
2 - Primarily or exclusively smear negative
8 - Not applicable
Did study include exclusively retreatment patients
upon enrolment? (for example, patients who previously received
first-line drugs and those with non-converting
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9 – Unknown/NR
Direction of study data collection 1 – Prospective
2 – Retrospective
9 – Unknown/NR
Number included after recruitment by inclusion and exclusion criteria _____
9 – Unknown/NR
Number included in analysis (# recruited − # withdrawals) _____
9 – Unknown/NR
Unit of analysis 1 – Patient (with a single Xpert per patient)
2 – Specimen (there are more specimens than patients)
9 – Unknown/NR
Describe as in paper, if unclear:
Comments about study design  
III. Patient characteristics and setting
Presenting signs and symptoms  
Did the study avoid inappropriate exclusions? Please list exclusions not-
ed in
study, if any (for example, study includes predominantly or exclusively




Describe exclusions as stated in study:
Type of specimen (may include expectorated, induced,
bronchial alveolar lavage (BAL), tracheal aspirates) (check all that apply).
Assume expectorated sputum if not specifically stated.
1 – Expectorated sputum
2 – Induced sputum
3 – Bronchial alveolar lavage or bronchial aspirates
4 – Tracheal aspirates
6 – Other
9 – Unknown/NR
If other, describe types and record numbers:
Clinical setting; describe as written in the paper 1 – Outpatient
2 - Inpatient
3 – Both out- and inpatient
4 – Other, specify
5 – Laboratory based
9 – Unknown/NR
  (Continued)
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Describe as in paper:
Was Xpert testing performed at point of care?
(POCT is diagnostic testing that will result in a
clear and actionable management decision (e.g.
start of treatment, referral, initiation of confirmatory
test) within the same clinical encounter (e.g. same
day). POCT should be mentioned in the study, as




9 - Could not tell
Level of the laboratory system where Xpert tests
were performed
(Tests generally available at different laboratory
levels, though tests may overlap)
Central: Intermediate laboratory tests and culture
on liquid media and DST (1st- and 2nd-line
antituberculosis drugs) on solid or in liquid media and line probe assay
(LPA)
on positive cultures and rapid speciation tests
Intermediate: Peripheral laboratory tests and
culture on solid media and LPA
from smear-positive sputum
Peripheral: AFB (Ziehl-Neelsen, Auramine-rhodamine,





Describe as in paper:
IV. Other demographics
Age (range, mean (SD), median (IQR)) 9 - Unknown/NR
##/total and % female 9 - Unknown/NR
HIV status of participants 0 - HIV -
1 - HIV +
2 - Both HIV+/-
9 - Unknown/NR
If HIV-positive participants included, what is the percentage? % (specify numerator/denominator)
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9 - Unknown/NR
If so, what is the percentage? % (specify numerator/denominator)
9 - Unknown/NR (for data entry write "NR")





If so, what is the percentage? % (specify numerator/denominator)
9 - Unknown/NR (for data entry write "NR")
Current treatment: Were patients on treatment (defined as tuberculosis
drugs for
greater than 7 days) for the current tuberculosis episode?




If so, what is the percentage? % (specify numerator/denominator)
9 - Unknown/NR (for data entry write "NR")
V. Index test
Xpert version(s) evaluated 1 - Xpert MTB/RIF only
2 - Xpert Ultra only
3 - Any combination Xpert MTB/RIF and Xpert Ultra
Xpert platform: Was Omni used? Unless Omni explicitly described, as-
sume
standard platform
1 – Yes, only Omni used for Xpert tests
2 – Yes, both Omni and standard platform used for Xpert
tests
3 - No
Was the index test result interpreted without knowledge of the result of
the reference standard result?




For tuberculosis detection, what reference standard(s) was used? 1 – Solid culture (specify 1a)
2 – Liquid culture (specify 2a)
3 – Both solid and liquid culture (specify 1a and 2a)
9 – Unknown/NR
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Other
9 - Unknown/NR




For MGIT only, if more than one specimen was inoculated for
culture, were these specimens obtained on different days?
1 – Yes
2 – No
8 – Not applicable
9 – Unknown/NR
For rifampicin resistance detection, what reference standard(s)
was used?
1 – Solid culture (specify 1a)
2 – Liquid culture (specify 2a)
3 – Both solid and liquid culture (specify 1a and 2a)
4 - Line probe assays, MTBDRplus (specify other)
5 - Other, specify
9 – Unknown/NR





Specify method, e.g. proportion
2a – Liquid culture
MGIT 960
Other (specify)
Tuberculosis detection: Was the reference standard result interpreted
without knowledge of the index test result?




Did the study speciate mycobacteria isolated in culture? 1 – Yes
2 – No
9 – Unknown/NR
Rifampicin resistance detection: Was the reference standard
result interpreted without knowledge of the index test result?





Were Xpert sample and culture obtained from same specimen? 1 – Yes
  (Continued)
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2 – No
9 – Unknown/NR




3 – NaOH (PetroL)
4 – Other
9 – Unknown/NR
Was microscopy used? 1 – Yes
2 – No
9 – Unknown/NR
Type of microscopy used 1 – Ziehl-Neelsen
2 – Fluorescence microscopy
3 - Both Ziehl-Neelsen and fluorescence microscopy
9 – Unknown/NR
Smear type (if study used both direct and concentrated,
select concentrated)
1 – Direct
2 – Concentrated (processed)
9 – Unknown/NR




3 - Both fresh and frozen
9 – Unknown/NR
VIII. Results
Did the study report % contaminated cultures?
(Enter percentage contaminated cultures, if
provided):
# of contaminated cultures/Total # cultures performed = %
1 – Yes -> % contaminated cultures:
2 – No
Did the study report the number of non-determinate
results for Xpert for tuberculosis detection? (invalid, error, no result)
The non-determinate rate for detection of PTB is the
number of tests classified as “invalid”, “error”, or “no result”
divided by the total number of Xpert tests performed.
1 – Yes -> # non-determinate results:
Denominator is total number of Xpert tests performed
(add total from Table 1 plus # of non-determinate re-
sults):
2 – No
Did the study report the number of indeterminate results for
Xpert for rifampicin resistance detection?
The indeterminate rate for detection of rifampicin resistance
was the number of tests classified as “MTB detected; Rif
resistance INDETERMINATE” divided by the total number
of Xpert-MTB positive results.
1 – Yes -># indeterminate results:
(Enter 0 indeterminate results if the total number in
Table 6 = the number of TPs in Table 1)
Denominator is total number of Xpert tests performed
(Total Xpert positive results from Table 1 first row):
2 – No
Did the study report any Xpert rifampicin resistant positive
results in culture-negative specimens?
1 – Yes -> number reported:
2 – No
  (Continued)
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Did the study report nontuberculous mycobacteria (NTM)?
Record number NTM over the number of cultures performed
1 – Yes -> number reported:
2 – No
If NTMs were identified, record number of Xpert positive
results among NTMs









Confirmed tuberculosisTuberculosisdetection, all participants
Yes No
Total
Positive      
Negative      
Xpert Ultra result





Confirmed tuberculosisTuberculosis detection, smear positive
Yes No
Total
Positive      
Negative      
Xpert Ultra result





Confirmed tuberculosisTuberculosisdetection, smear negative
Yes No
Total
Positive      Xpert Ultra
Negative      
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Confirmed tuberculosisTuberculosisdetection, 'trace' results
Yes No
Total
Positive      
Negative      
Xpert Ultra








Positive      
Negative      
Xpert Ultra
Total      
 
 
Appendix 3. Rules for QUADAS-2 and QUADAS-C
In QUADAS-2, we assessed methodological quality separately for each of the objectives, Xpert for pulmonary tuberculosis detection and
Xpert for rifampicin resistance detection.
Domain 1: Patient selection
Xpert Ultra or Xpert MTB/RIF for pulmonary tuberculosis detection
Risk of bias: Could the selection of patients have introduced bias?
Signalling question 1: Was a consecutive or random sample of patients enrolled? We answered ‘yes' if the study enrolled a consecutive or
random sample of eligible patients; ‘no' if the study selected patients by convenience; and ‘unclear' if the study did not report the manner
of patient selection or we could not tell.
Signalling question 2: Was a case-control design avoided? Studies using a case-control design were not included in the review because
this study design, especially when used to compare results in severely ill patients with those in relatively healthy individuals, may lead to
overestimation of accuracy in diagnostic studies. We answered ‘yes' for all studies.
Signalling question 3: Did the study avoid inappropriate exclusions? We answered ‘yes' if the study included both smear-positive and smear-
negative individuals; ‘no' if the study included primarily or exclusively smear-positive or smear-negative patients; and ‘unclear' if we could
not tell. We also answered ‘no' if the study included primarily or exclusively patients who had undergone previous treatment (retreatment
patients).
In our 'Risk of bias' judgement, we also considered the condition of the specimen, and whether the study used fresh or frozen specimens.
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Applicability: Are there concerns that the included patients and setting do not match the review question?
We were interested in how Xpert MTB/RIF or Xpert Ultra performed in patients who were evaluated as they would be in routine practice. We
answered ‘low concern' if patients were evaluated in local hospitals or primary care centres. We answered ‘high concern' if patients were
evaluated exclusively as inpatients in tertiary care centres or if the setting did not match the review question, for example using the index
for decisions about the need for airborne isolation. We answered ‘unclear concern' if the clinical setting was not reported or information
was insuLicient to make a decision. We also answered ‘unclear concern' if Xpert MTB/RIF or Xpert Ultra testing was done at a central-level
laboratory, and the clinical setting was not reported for the following reason: it was diLicult to tell if a given reference laboratory provided
services mainly to very sick patients.
Xpert Ultra or Xpert MTB/RIF for rifampicin resistance detection
Domain 1: Patient selection is the same as for Xpert for pulmonary tuberculosis detection except for the following.
Signalling question 3: Did the study avoid inappropriate exclusions? We answered ‘yes' if the study included both smear-positive and smear-
negative individuals; ‘no' if the study included primarily or exclusively smear-positive or smear-negative patients; and ‘unclear' if we could
not tell. We answered ‘yes' if the study included primarily or exclusively retreatment patients because the group at risk for rifampicin
resistance includes patients who had undergone previous treatment.
Domain 2: Index test
Xpert Ultra or Xpert MTB/RIF for pulmonary tuberculosis detection
Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
Signalling question 1: Were the index test results interpreted without knowledge of the results of the reference standard? We answered this
question ‘yes' for all studies because Xpert test results were automatically generated, and the user was provided with printable test results,
thus there is no room for subjective interpretation of test results.
Signalling question 2: If a threshold was used, was it prespecified? The threshold was prespecified in all versions of Xpert. We answered this
question ‘yes' for all studies.
For risk of bias, we judged ‘low concern' for all studies.
Applicability: Are there concerns that the index test, its conduct, or its interpretation diLer from the review question? Variations in test
technology, execution, or interpretation may aLect estimates of the diagnostic accuracy of a test. All steps in the Xpert MTB/RIF and Xpert
Ultra assays are completely automated and self-contained following sample loading. We answered ‘low concern' if the index test was
performed as recommended by the manufacturer, which was true for most studies. We answered ‘unclear concern' if the ratio of the Xpert
Ultra or Xpert MTB/RIF sample reagent: specimen volume was not 2:1 for a raw specimen or 3:1 for a sediment, as recommended by the
manufacturer. Central-level laboratories use more highly trained staL than peripheral and intermediate-level laboratories. However, we
did not consider this to be a concern about applicability because, in some studies, the reason the index test was performed in a central-level
laboratory was the requirement for a sophisticated laboratory infrastructure to perform culture (reference standard) not to perform Xpert.
Xpert Ultra or Xpert MTB/RIF for rifampicin resistance detection
Domain 2: Index test is the same as for Xpert for pulmonary tuberculosis detection.
Domain 3: Reference standard
Xpert Ultra or Xpert MTB/RIF for pulmonary tuberculosis detection
Risk of bias: Could the reference standard, its conduct, or its interpretation have introduced bias?
Signalling question 1: Is the reference standard likely to correctly classify the target condition?
For the reference standard, all studies used culture, which is generally considered to be the best reference standard for tuberculosis. Two
studies used a composite reference standard in addition to culture. We answered this signalling question 'yes' for all studies.
Signalling question 2: Were the reference standard results interpreted without knowledge of the results of the index test?
We answered ‘yes' if the reference test provided an automated result (e.g. MGIT 960), blinding was explicitly stated, or it was clear that the
reference standard was performed at a separate laboratory and/or performed by diLerent people. We answered ‘no' if the study stated
that the reference standard result was interpreted with knowledge of the index test result. We answered ‘unclear' if we could not tell.
Applicability: Are there concerns that the target condition as defined by the reference standard does not match the question? We answered
‘high concern' if the included studies did not speciate mycobacteria isolated in culture; ‘low concern' if speciation was performed; and
‘unclear concern' if we could not tell.
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Xpert Ultra or Xpert MTB/RIF for rifampicin resistance detection
Risk of bias: Could the selection of patients have introduced bias?
Signalling question 1: Is the reference standard likely to correctly classify the target condition?
We answered ‘yes' if either culture-based drug susceptibility testing or a line probe assay such as MTBDRplus was used. These were criteria
for inclusion for this objective of the review.
Signalling question 2: Were the reference standard results interpreted without knowledge of the results of the index test?
We answered ‘yes' if the reference test provided an automated result (e.g. MGIT 960), blinding was explicitly stated, or it was clear that the
reference standard was performed at a separate laboratory and/or performed by diLerent people. We answered ‘no' if the study stated
that the reference standard result was interpreted with knowledge of the Xpert Ultra or Xpert MTB/RIF test result. We answered ‘unclear'
if we could not tell.
Applicability: Are there concerns that the target condition as defined by the reference standard does not match the question? We judged
applicability to be of ‘low concern' for those studies evaluating Xpert for rifampicin resistance because these specimens had already been
identified as Mycobacterium tuberculosis positive.
Domain 4: Flow and timing
Xpert Ultra or Xpert MTB/RIF for pulmonary tuberculosis detection
Risk of bias: Could the patient flow have introduced bias?
Signalling question 1: Was there an appropriate interval between the index test and reference standard? We expected that in most included
studies specimens for Xpert MTB/RIF or Xpert Ultra and culture would be obtained at the same time, when patients were evaluated for
presumptive pulmonary tuberculosis. However, even if there was a delay of several days between index test and reference standard,
tuberculosis is a chronic disease, and we considered misclassification of disease status to be unlikely, as long as treatment was not initiated
in the interim. We answered ‘yes' if the index test and reference standard were performed at the same time, or if the time interval was less
than or equal to seven days; ‘no' if the time interval was greater than seven days; or ‘unclear' if we could not tell.
Signalling question 2: Did all patients receive the same reference standard? We answered this question ‘yes' for all studies, as an acceptable
reference standard (either solid or liquid culture) was specified as a criterion for inclusion in the review. We acknowledge that it is possible
that some specimens could undergo solid culture and others liquid culture, which could potentially result in variations in accuracy;
however, we thought the variation would be minimal.
Signalling question 3: Were all patients included in the analysis? We determined the answer to this question by comparing the number of
patients enrolled with the number of patients included in the 2 x 2 tables. We answered ‘yes' if the numbers matched, and ‘no' if there were
patients enrolled in the study that were not included in the analysis. We answered ‘unclear' if we could not tell.
Xpert Ultra or Xpert MTB/RIF for rifampicin resistance detection
Domain 4: Flow and timing is the same as for Xpert Ultra or Xpert MTB/RIF for pulmonary tuberculosis detection.
Judgements for ‘Risk of bias' assessments for a given domain are as follows.
• If we answered all signalling questions for a domain ‘yes', then we judged risk of bias as ‘low'.
• If we answered all or most signalling questions for a domain ‘no', then we judged risk of bias as ‘high'.
• If we answered only one signalling question for a domain ‘no', we further discussed the ‘Risk of bias' judgement.
• If we answered all or most signalling questions for a domain ‘unclear', then we judged risk of bias as ‘unclear'.
• If we answered only one signalling question for a domain ‘unclear', we further discussed the ‘Risk of bias' judgement for the domain.
Comparative accuracy (QUADAS-C): Xpert Ultra versus Xpert MTB/RIF




Comparison of index tests: Describe how patients were selected to undergo each of the index tests in the comparison. If randomization
was used to assign individual patients (or clusters of patients) to index tests, describe the randomization process. Add flow diagram if
available.
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Domain: Patient selection
Single test accuracy (QUADAS-2) Xpert Ultra Xpert MTB/
RIF























Comparative accuracy (QUADAS-C) Xpert Ultra vs Xpert MTB/
RIF
1 Was risk of bias for this domain judged ‘low’ for all index
tests?
Yes/No/Unclear
2 Was the intention for patients either to receive all index tests
or to be randomly allocated to index tests?
Yes/No/Unclear




4 If patients were randomized, was the allocation sequence





5 Were separate, sputum specimens tested with both tests or
split raw sputum allocated and tested at random?
Yes/No/Unclear
Not applicable




Single test accuracy (QUADAS-2) Xpert Ultra Xpert MTB/
RIF
1 Were the index test results interpreted without knowledge of
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Concerns regarding applicability Are there concerns that the index test, its conduct, or its inter-





Comparative accuracy (QUADAS-C) Xpert Ultra vs Xpert MTB/
RIF
1 Was risk of bias for this domain judged ‘low’ for all index
tests?
Yes/No/Unclear
2 If patients received multiple index tests, were test results in-




3 If patients received multiple index tests, is undergoing one





4 Were differences in the conduct or interpretation between
the index tests unlikely to advantage one of the tests?
Yes/No/Unclear
Risk of bias Could the conduct or interpretation of the index tests have in-
troduced bias in the comparison?
Low/High/Unclear
Domain: Reference standard
Single test accuracy (QUADAS-2) Xpert Ultra Xpert MTB/
RIF
























Are there concerns that the target condition as defined by the reference standard does not





Comparative accuracy (QUADAS-C) Xpert Ultra vs Xpert MTB/
RIF




2 Did the reference standard avoid incorporating any of the index tests? Yes/No/Unclear
Risk of
bias
Could the reference standard, its conduct, or its interpretation have introduced bias in the
comparison?
Low/High/Unclear
Domain: Flow and timing
  (Continued)
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Single test accuracy (QUADAS-2) Xpert Ultra Xpert MTB/
RIF



















Comparative accuracy (QUADAS-C) Xpert Ultra vs Xpert MTB/
RIF
1 Was risk of bias for this domain judged ‘low’ for all index tests? Yes/No/Unclear
2 Was there an appropriate interval between the index tests? Yes/No/Unclear
3 Was the same reference standard used for all index tests? Yes/No/Unclear
Signalling questions
4 Are the proportions and reasons for missing data similar across index tests? Yes/No/Unclear
Risk of bias Could the patient flow have introduced bias in the comparison? Low/High/Unclear
  (Continued)
 
Appendix 4. Statistical appendix
Bayesian bivariate hierarchical model
The Bayesian bivariate hierarchical model used for the meta-analyses is summarized below. The hierarchical framework took into account
heterogeneity between studies and also between centres within two of the largest studies. The model was derived as an extension of
previously described models (Chu 2009; Reitsma 2005). An OpenBUGS program to fit this model is provided below. Three independent,
dispersed sets of starting values were used to run separate chains. The Gelman-Rubin statistic within the OpenBUGS program was used to
assess convergence. No convergence problems were observed. The first 10,000 iterations were treated as burn-in iterations and dropped.
Summary statistics were obtained based on a total of 150,000 iterations resulting from the three separate chains.
Notation: From the jth centre in the ith study we extracted the cross-tabulation between the index and reference tests TPij, FPij, TNij, FNij.
The sensitivity in ijth study is denoted by Sij and the specificity by SPij. We denote the Binomial probability distribution with sample size
N and probability p as Binomial(p,N), the Bivariate Normal probability distribution with mean vector μ and variance-covariance matrix Σ
as BVN(μ, Σ), the univariate Normal distribution with mean m and variance s by N(m, s) and the Uniform probability distribution between
a and b by Uniform(a,b).
Likelihood Figure 13
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Figure 13.   Bayesian bivariate hierarchical model, likelihood.
 
The pooled sensitivity is given by 1/1+exp (-μ1) and pooled specificity as 1/1+exp (μ2).
Prior distributions Figure 14.
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Figure 14.   Bayesian bivariate hierarchical model, prior distributions.
 
Prior distributions were placed over the coeLicients in the linear function: a1 and a2~ N(0,4) and b1 and b2~ N(0,1.39) (Buzoianu 2008).
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
# BIVARIATE MODEL ASSUMING PERFECT CULTURE REFERENCE TEST
model {










l[i,1:2] ~ dmnorm(mu[1:2], T[1:2,1:2])
}
############################# HYPER PRIOR DISTRIBUTIONS
mu[1] ~ dnomr(0.0.25) # replaced by mu[1] ~ dnorm(0,0.01) in sensitivity analysis to check impact of less informative prior
mu[2] ~ dnomr(0.0.25) # replaced by mu[2] ~ dnorm(0,0.01) in sensitivity analysis to check impact of less informative prior
T[1:2,1:2]<-inverse(TAU[1:2,1:2])





tau[1] <- pow(prec[1],-0.5) # replaced by tau[1] ~ dunif(0,3) in sensitivity analysis to check impact of less informative prior
tau[2] <- pow(prec[2],-0.5) # replaced by tau[2] ~ dunif(0,3) in sensitivity analysis to check impact of less informative prior
#### prec = between-study precision in the logit(sensitivity)and logit(specificity)
prec[1] ~ dgamma(2,0.5) # replaced by prec[1] <- powtau[1],-2) in sensitivity analysis to check impact of less informative prior
prec[2] ~ dgamma(2,0.5) # replaced by prec[2] <- powtau[2],-2) in sensitivity analysis to check impact of less informative prior
rho ~ dunif(-1,1)
############################# OTHER PARAMETERS OF INTEREST
#### POOLED SENSITIVITY AND SPECIFICITY
Pooled_S<-1/(1+exp(-mu[1]))
Pooled_C<-1/(1+exp(-mu[2]))




TP[] FP[] FN[] TN[]
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50 8 6 173
175 1 25 76
408 43 54 934
62 18 10 149
45 5 2 144
23 10 0 147
116 3 7 140
END
# row 1 Berhanu 2018
# row 2 Chakravorty 2017
# row 3 Dorman 2018
# row 4 Mishra 2019a
# row 5 Opota 2019
# row 6 Pereira 2020
# row 7 Piersimoni 2019
Appendix 5. Bayesian bivariate hierarchical model
Figure 13 Bayesian bivariate hierarchical model, likelihood
Figure 14 Bayesian bivariate hierarchical model, prior distributions
Appendix 6. QUADAS-C judgements, pulmonary tuberculosis
Figure 15
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Figure 15.   Table. Risk of bias concerns summary for detection of pulmonary tuberculosis: review authors'
judgements about each domain for each included study, QUADAS-C judgements. P: Patient selection, I: Index test, R:
Reference standard, FT: Flow and Timing
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Appendix 7. QUADAS-C judgements, rifampicin resistance
Figure 16
 
Figure 16.   Table. Risk of bias concerns summary for detection of rifampicin resistance: review authors' judgements
about each domain for each included study, QUADAS-C judgements. P: Patient selection, I: Index test, R: Reference
standard, FT: Flow and Timing
 




ALiliation: University of Cape Town
I certify that I have no aEiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.
In the initial version of Steingart et al's systematic review of the Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance
in adults (Steingart 2013) includes 15 studies where Xpert MTB/RIF was used as an initial test replacing smear microscopy, with the majority
of patients being drawn from two major studies (Boehme 2010, Boehme 2011). My comment relates to the appropriate reference standard
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for tuberculosis is these studies. The systematic review appraised the quality of included studies with the Quality Assessment of Diagnostic
Accuracy Studies (QUADAS-2) (Whiting 2011) tool which states that estimates of test accuracy are based on the assumption that the
reference standard is 100% sensitive and that specific disagreements between the reference standard and index test result from incorrect
classification by the index test.
For each of the studies in question the reference standard for tuberculosis is listed as “Löwenstein-Jensen culture and MGIT 960” and the
review considers that the reference standard is likely to correctly classify the target condition. There is considered to be low risk of bias or
applicability concerns relating to the reference test.
However, in Boehme et al 2010 there were 105 patients with ‘clinical tuberculosis’ who were excluded from the analysis. These patients
were negative by the reference standard of Löwenstein-Jensen culture and MGIT 960 and should have been included in the ‘no tuberculosis’
group. In Boehme et al 2011 there were 153 similar patients who were excluded from the analysis.
Neither paper gives justification for the exclusion of these patients who according to QUADAS-2 were negative by the reference standard
and should be included in the ‘no tuberculosis’ group. Ideally the systematic review should be amended to include these patients but if
the data is unavailable the risk of bias should be acknowledged.
Note from the Editors: In addition to the above feedback, Boyles et al. published a case study in The International Journal of Tuberculosis and
Lung Disease which outlined the above arguments, and illustrates this with a case study (Boyles 2014 ); which the Cochrane authors respond
to, in the same journal (see below).
Reply
The review authors thank Boyles et al. for this comment. They raise important points about the selective exclusion of culture negative
clinical tuberculosis cases in the Boehme studies.
We considered the published case study (Boyles 2014) in detail, and in response we carried out additional analyses to determine whether
the Boehme studies unduly influenced the overall findings of this Cochrane review. One way we did this was by repeating the meta-
analysis with studies for which we could extract data for all enrolled participants, including patients classified as ‘clinical tuberculosis’ with
negative sputum culture. We considered these participants as not having tuberculosis. In the new analysis, we found pooled sensitivity
and specificity estimates to be similar to those we previously reported.
We published our findings as a response to Boyles et al. in The International Journal of Tuberculosis and Lung Disease (Steingart 2015).
In the updated Cochrane Review, for Boehme 2010, we included culture negative results (clinical tuberculosis cases) in determinations of
Xpert MTB/RIF specificity. For Boehme 2011, we did not have data for clinical tuberculosis, and therefore, in the flow and timing domain,
we changed our judgement for risk of bias to ‘high'.
W H A T ' S   N E W
 
Date Event Description
17 February 2021 New citation required and conclusions
have changed
To extend the work of our previous Cochane Review (Horne
2019), we performed this review update to inform updates to
WHO policy.
17 February 2021 New search has been performed We updated the literature search to 28 January 2020. Prespecifed
changes to the protocol for this review update are given in Table
8.
 
H I S T O R Y
Protocol first published: Issue 1, 2012
Review first published: Issue 1, 2013
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Date Event Description
5 June 2019 New citation required but conclusions
have not changed
The findings in this update are consistent with those reported
previously (Steingart 2014).
5 June 2019 New search has been performed We identified 95 unique studies, integrating 77 new studies since
publication of the Cochrane Review (Steingart 2014).
30 June 2015 Amended See Steingart 2014 for these amendments. Added revised data
including (smear-positive culture negatives) for Boehme 2010
and Rachow 2011. Added corrected data for Hanrahan 2013.
Added test and analysis for history of tuberculosis (TB). Amend-
ed patient selection for Boehme 2011 to high risk of bias.
16 March 2015 Feedback has been incorporated Feedback from Dr Tom Boyles at University of Cape Town has
been incorporated and responded to.
6 May 2014 Amended See Steingart 2014 for this amendment. Following information
obtained from a trial author, details of the version of Xpert MTB/
RIF used in Balcells 2012 have been corrected.
13 February 2014 Amended Sentence moved in Abstract; corrected "pooled median sensitivi-
ty" to "median pooled sensitivity" throughout.
30 November 2013 New citation required but conclusions
have not changed
We conducted a new search and revised the review as described.
30 November 2013 New search has been performed 1. We performed an updated literature search on 7 February
2013.
2. For smear microscopy as a comparator test, we added a de-
scriptive plot showing the estimates of sensitivity and specifici-
ty of Xpert compared with those of smear microscopy in studies
that reported on both tests.
3. We included studies using Xpert version G4 (two studies) and
studies evaluating Xpert in primary care clinics (two studies).
These studies did not change the overall findings.
4. We improved the QUADAS-2 assessment concerning applica-
bility.
5. For TB detection, we repeated our earlier meta-regression
analyses within subgroups defined by smear status.
6. For rifampicin resistance detection, we performed univariate
meta-analyses for sensitivity and specificity separately in order
to include studies in which no rifampicin resistance was detect-
ed. We also performed a sensitivity analysis using the bivariate
random-effects model for the subset of studies that provided da-
ta for both sensitivity and specificity.
7. We revised the 'Summary of findings' table to include clini-
cal scenarios with prevalence levels recommended by the World
Health Organization.
8. In the Background, we shortened the section on alternative
tests to include only those tests most relevant to the review.
9. We added health economic considerations to the Discussion.
10. We added updated TB surveillance information.
17 January 2013 Amended We made minor edits to the text to correct typographical errors.
In addition, we replaced Figures 6, 8, 11, and 13 with new figures
with minor modifications to the prediction regions.
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External sources
• United States Agency for International Development (USAID), USA
Development of this project was in part made possible with financial support from USAID administered by the World Health Organization
Global Tuberculosis Programme
• Foreign, Commonwealth and Development OLice (FCDO), UK
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
Table 8 describes prespecified changes for this review update. We performed the review as a comparative review and changed the
title to 'Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary
tuberculosis'. In addition, we restated the objective as: to compare the diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF for detection
of pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis.
We clarified types of studies: we included cross-sectional and cohort type diagnostic accuracy studies that directly compared the index tests
in participants with presumptive pulmonary tuberculosis. These study designs included paired and randomized comparative accuracy
studies. Paired comparative accuracy studies are those in which each participant receives both index tests. Randomized comparative
accuracy studies are those which randomly allocate participants to index tests, with each participant receiving only one index test.
In the protocol, we stated that we would extract data on industry sponsorship. As both Xpert Ultra and Xpert MTB/RIF are available at a
concessional price for researchers in resource-limited settings, and are well-established tests, especially Xpert MTB/RIF, industry donation
is rarely pursued, thus we did not consider that the additional analysis would have added value. We acknowledge that, in addition to
funding, there are other reasons for conflicts of interest; however, we did not have time to pursue these. We are aware of a new tool being
developed for this purpose: TACIT (Tool for Addressing Conflicts of Interest in Trials, tacit.one). We plan to avail ourselves of this new tool
in updates of this review.
We summarized the frequency of Xpert Ultra trace-positive results, as well as the frequency of trace results in individuals with a history
of tuberculosis.
We used QUADAS-2 and QUADAS-C to assess risk of bias in the included studies.
We planned to estimate the predicted sensitivity and specificity in a future study together with their 95% CrIs. Instead, we determined
predictive values, which we thought would be more useful clinically.
We planned to perform a sensitivity analysis for studies that accounted for all participants in the analysis; however, for the detection of
pulmonary tuberculosis, this criterion was satisfied by all studies.
We did not perform sensitivity analyses for Xpert MTB/RIF, as we performed these analyses in the previous Cochrane Review update,
with most of these analyses including greater than 50 studies (Horne 2019). These sensitivity analyses did not change Xpert MTB/RIF
performance.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Antibiotics, Antitubercular  [pharmacology];  *Drug Resistance, Bacterial;  Microbial Sensitivity Tests;  *Mycobacterium tuberculosis
 [drug eLects];  *Rifampin  [pharmacology];  Sensitivity and Specificity;  *Tuberculosis, Pulmonary  [drug therapy]
MeSH check words
Humans
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